Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Jan. 31, 2018	Mar. 23, 2018	Jul. 31, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	STREAMLINE HEALTH SOLUTIONS INC.
Entity Central Index Key	0001008586
Document Type	10-K
Document Period End Date	Jan. 31, 2018
Amendment Flag	false
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--01-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 18,743,172
Entity Common Stock, Shares Outstanding		19,984,703

Consolidated Balance Sheets - USD ($)	Jan. 31, 2018	Jan. 31, 2017
Current assets:
Cash and cash equivalents	$ 4,619,834	$ 5,654,093
Accounts receivable, net of allowance for doubtful accounts of $349,058 and $198,449, respectively	3,001,170	4,489,789
Contract receivables	223,791	466,423
Prepaid hardware and third party software for future delivery	5,858	5,858
Prepaid client maintenance contracts	506,911	595,633
Other prepaid assets	742,232	732,496
Other current assets	546,885	439
Total current assets	9,646,681	11,944,731
Property and equipment:
Computer equipment	2,852,776	3,110,274
Computer software	730,950	827,642
Office furniture, fixtures and equipment	683,443	683,443
Leasehold improvements	729,348	729,348
Property and equipment, gross	4,996,517	5,350,707
Accumulated depreciation and amortization	(3,834,153)	(3,447,198)
Property and equipment, net	1,162,364	1,903,509
Capitalized software development costs, net of accumulated amortization of $18,658,183 and $16,544,797, respectively	4,307,351	4,584,245
Intangible assets, net	5,835,151	6,996,599
Goodwill	15,537,281	15,537,281
Other non-current assets	642,226	672,133
Total non-current assets	27,484,373	29,693,767
Total assets	37,131,054	41,638,498
Current liabilities:
Accounts payable	421,425	1,116,525
Accrued compensation	342,351	496,706
Accrued other expenses	609,582	484,391
Current portion of term loan	596,984	655,804
Deferred revenues	9,481,807	9,916,454
Current portion of capital lease obligations	0	91,337
Total current liabilities	11,452,149	12,761,217
Non-current liabilities:
Term loan, net of current portion and deferred financing cost of $128,275 and $199,211, respectively	3,901,353	4,883,286
Warrants liability	0	46,191
Royalty liability	2,469,193	2,350,754
Lease incentive liability, less current portion	274,128	339,676
Deferred revenues, less current portion	332,645	568,515
Total non-current liabilities	6,977,319	8,188,422
Total liabilities	18,429,468	20,949,639
Series A 0% Convertible Redeemable Preferred Stock, $.01 par value per share, $8,849,985 redemption and liquidation value, 4,000,000 shares authorized, 2,949,995 issued and outstanding	8,849,985	8,849,985
Stockholders’ equity:
Common stock, $.01 par value per share, 45,000,000 shares authorized; 20,005,977 and 19,695,391 shares issued and outstanding, respectively	200,060	196,954
Additional paid in capital	81,776,606	80,667,771
Accumulated deficit	(72,125,065)	(69,025,851)
Total stockholders’ equity	9,851,601	11,838,874
Total liability and stockholders' equity	$ 37,131,054	$ 41,638,498

Consolidated Balance Sheets (Parenthetical) - USD ($)	12 Months Ended
Consolidated Balance Sheets (Parenthetical) - USD ($)	Jan. 31, 2018	Jan. 31, 2017
Allowance for doubtful accounts	$ 349,058	$ 198,449
Accumulated amortization of capitalized software development costs	18,658,183	16,544,797
Deferred financing costs, accumulated amortization	$ 128,275	$ 199,211
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	45,000,000	45,000,000
Common stock, shares issued (in shares)	20,005,977	19,695,391
Common stock, shares outstanding (in shares)	20,005,977	19,695,391
Series A Preferred Stock
Preferred stock dividend rate (as a percent)	0.00%	0.00%
Convertible redeemable preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable preferred stock, liquidation and redemption value	$ 8,849,985	$ 8,849,985
Convertible redeemable preferred stock, shares authorized (in shares)	4,000,000	4,000,000
Convertible redeemable preferred stock, shares issued (in shares)	2,949,995	2,949,995
Convertible redeemable preferred stock, shares outstanding (in shares)	2,949,995	2,949,995
Unamortized preferred stock discount	$ 0	$ 0

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Jan. 31, 2018	Jan. 31, 2017
Revenues:
Systems sales	$ 1,343,288	$ 2,512,579
Professional services	2,744,070	2,395,987
Audit services	1,216,285	627,919
Maintenance and support	13,170,644	14,809,935
Software as a service	5,863,788	6,713,485
Total revenues	24,338,075	27,059,905
Operating expenses:
Cost of systems sales	1,946,347	2,712,663
Cost of professional services	2,400,534	2,724,078
Cost of audit services	1,603,572	1,100,154
Cost of maintenance and support	2,904,181	3,226,511
Cost of software as a service	1,318,628	1,763,705
Selling, general and administrative	11,434,276	13,088,074
Research and development	5,352,189	7,453,638
Gain on sale of business	0	(238,103)
Total operating expenses	26,959,727	31,830,720
Operating loss	(2,621,652)	(4,770,815)
Other income (expense):
Interest expense	(474,657)	(508,859)
Miscellaneous (expense) income	(86,735)	106,084
Loss before income taxes	(3,183,044)	(5,173,590)
Income tax benefit	83,830	12,024
Net loss	(3,099,214)	(5,161,566)
Less: deemed dividends on Series A Preferred Shares	0	(875,935)
Net loss attributable to common shareholders	$ (3,099,214)	$ (6,037,501)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.16)	$ (0.31)
Weighted average number of common shares - basic and diluted (in shares)	19,876,383	19,528,341

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Total	Common stock	Additional paid in capital	Accumulated deficit
Stockholders' equity, beginning balance (in shares) at Jan. 31, 2016		18,783,540
Stockholders' equity, beginning balance at Jan. 31, 2016	$ 16,024,128	$ 187,836	$ 79,700,577	$ (63,864,285)
Statement of Changes in stockholders' equity
Stock issued pursuant to Employee Stock Purchase Plan (in shares)		67,667.00
Stock issued pursuant to Employee Stock Purchase Plan	76,582	$ 676	75,906
Restricted stock issued (in shares)		858,225
Restricted stock issued	0	$ 8,582	(8,582)
Surrender of stock upon vesting of restricted stock to satisfy tax withholding obligations (in shares)		(8,241.00)
Surrender of stock upon vesting of restricted stock to satisfy tax withholding obligations	(11,702)	$ (82)	(11,620)
Restricted stock forfeited (in shares)		(5,800.00)
Restricted stock forfeited	0	$ (58)	58
Share-based compensation expense	1,787,367		1,787,367
Deemed dividends on Series A Preferred Stock	(875,935)		(875,935)
Net loss	(5,161,566)			(5,161,566)
Stockholders' equity, ending balance (in shares) at Jan. 31, 2017		19,695,391
Stockholders' equity, ending balance at Jan. 31, 2017	11,838,874	$ 196,954	80,667,771	(69,025,851)
Statement of Changes in stockholders' equity
Stock issued pursuant to Employee Stock Purchase Plan (in shares)		47,282.00
Stock issued pursuant to Employee Stock Purchase Plan	44,513	$ 473	44,040
Restricted stock issued (in shares)		295,337.00
Restricted stock issued		$ 2,953	(2,953)
Surrender of stock upon vesting of restricted stock to satisfy tax withholding obligations (in shares)		(32,033.00)
Surrender of stock upon vesting of restricted stock to satisfy tax withholding obligations	(41,813)	$ (320)	(41,493)
Share-based compensation expense	1,109,241		1,109,241
Net loss	(3,099,214)			(3,099,214)
Stockholders' equity, ending balance (in shares) at Jan. 31, 2018		20,005,977
Stockholders' equity, ending balance at Jan. 31, 2018	$ 9,851,601	$ 200,060	$ 81,776,606	$ (72,125,065)

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Jan. 31, 2018	Jan. 31, 2017
Cash flows from operating activities:
Net loss	$ (3,099,214)	$ (5,161,566)
Adjustments to reconcile net loss to net cash provided by operating activities, net of effect of acquisitions:
Depreciation	774,074	1,099,957
Amortization of capitalized software development costs	2,113,385	2,771,437
Amortization of intangible assets	1,161,448	1,344,980
Amortization of other deferred costs	340,502	324,496
Valuation adjustment for warrants liability	(46,191)	(158,922)
Other valuation adjustments	141,038	94,009
Gain on sale of business	0	(238,103)
Loss (gain) on disposal of fixed assets	(15,947)	567
Share-based compensation expense	1,109,241	1,787,367
Provision for accounts receivable	233,550	121,025
Changes in assets and liabilities, net of assets acquired:
Accounts and contract receivables	1,497,701	(344,445)
Other assets	(695,444)	449,673
Accounts payable	(695,100)	(51,071)
Accrued expenses	(117,311)	(690,094)
Deferred revenues	(670,517)	(341,008)
Net cash provided by operating activities	2,031,215	1,008,302
Cash flows from investing activities:
Purchases of property and equipment	(48,616)	(506,040)
Proceeds from sales of property and equipment	19,959	0
Capitalization of software development costs	(1,836,491)	(1,978,946)
Payment for acquisition	0	(1,400,000)
Proceeds from sale of business	0	2,000,000
Net cash used in investing activities	(1,865,148)	(1,884,986)
Cash flows from financing activities:
Principal repayments on term loans	(1,111,689)	(2,796,590)
Payments related to settlement of employee shared-based awards	(41,813)	(11,702)
Principal payments on capital lease obligations	(91,337)	(569,189)
Proceeds from exercise of stock options and stock purchase plan	44,513	26,122
Net cash used in financing activities	(1,200,326)	(3,351,359)
Decrease in cash and cash equivalents	(1,034,259)	(4,228,043)
Cash and cash equivalents at beginning of year	5,654,093	9,882,136
Cash and cash equivalents at end of year	4,619,834	5,654,093
Supplemental cash flow disclosures:
Interest paid	418,058	441,951
Income taxes paid	7,594	5,290
Supplemental disclosure of non-cash financing activities:
Deemed dividends on Series A Preferred Stock	$ 0	$ 875,935

Organization and Description of Business	12 Months Ended
Organization and Description of Business	Jan. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	ORGANIZATION AND DESCRIPTION OF BUSINESS Streamline Health Solutions, Inc. and its subsidiary (“we”, “us”, “our”, “Streamline”, or the “Company”) operates in one segment as a provider of healthcare information technology solutions and associated services. The Company provides these capabilities through the licensing of its HIM, Coding & CDI, eValuator^TM Coding Analysis Platform, Financial Management and Patient Care solutions and other workflow software applications and the use of such applications by software as a service (“SaaS”). The Company also provides audit services to help clients optimize their internal clinical documentation and coding functions, as well as implementation and consulting services to complement its software solutions. The Company’s software and services enable hospitals and integrated healthcare delivery systems in the United States and Canada to capture, store, manage, route, retrieve and process patient clinical, financial and other healthcare provider information related to the patient revenue cycle. Fiscal Year All references to a fiscal year refer to the fiscal year commencing February 1 in that calendar year and ending on January 31 of the following calendar year.

Significant Accounting Policies

12 Months Ended

Jan. 31, 2018

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and its wholly-owned subsidiary, Streamline Health, Inc. All significant intercompany transactions and balances are eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to stock-based compensation, capitalization of software development costs, intangible assets, allowance for doubtful accounts, and income taxes. Actual results could differ from those estimates.

Cash and Cash Equivalents

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash demand deposits. Cash deposits are placed in Federal Deposit Insurance Corporation (“FDIC”) insured financial institutions. Cash deposits may exceed FDIC insured levels from time to time. For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly-liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Receivables

Accounts and contract receivables are comprised of amounts owed to the Company for licensed software, professional services, including coding audit and maintenance services, and software as a service and are presented net of the allowance for doubtful accounts. The timing of revenue recognition may not coincide with the billing terms of the client contract, resulting in unbilled receivables or deferred revenues; therefore certain contract receivables represent revenues recognized prior to client billings. Individual contract terms with clients or resellers determine when receivables are due. For billings where the criteria for revenue recognition have not been met, deferred revenue is recorded until all revenue recognition criteria have been met.

Allowance for Doubtful Accounts

In determining the allowance for doubtful accounts, aged receivables are analyzed monthly by management. Each identified receivable is reviewed based upon the most recent information available and the status of any open or unresolved issues with the client preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. During these monthly reviews, the Company determines the required allowances for doubtful accounts for estimated losses resulting from the unwillingness or inability of its clients or resellers to make required payments. The allowance for doubtful accounts was approximately $349,000 and $198,000 at January 31, 2018 and 2017, respectively. The Company believes that its reserve is adequate, however results may differ in future periods.

Bad debt expense for fiscal years 2017 and 2016 was as follows:



	2017		2016
Bad debt expense	$	234,000	$	121,000

Concessions Accrual

In determining the concessions accrual, the Company evaluates historical concessions granted relative to revenue. The concession accrual included in accrued other expenses on the Company's consolidated balance sheet was $48,000 and $52,000 as of January 31, 2018 and 2017, respectively.

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related assets. Estimated useful lives are as follows:



Computer equipment and software	3-4 years
Office equipment	5 years
Office furniture and fixtures	7 years
Leasehold improvements	Term of lease or estimated useful life, whichever is shorter

Depreciation expense for property and equipment in fiscal 2017 and 2016 was $774,000 and $1,100,000, respectively.

Normal repair and maintenance is expensed as incurred. Replacements are capitalized and the property and equipment accounts are relieved of the items being replaced or disposed of, if no longer of value. The related cost and accumulated depreciation of the disposed assets are eliminated and any gain or loss on disposition is included in the results of operations in the year of disposal.

Leases

On December 13, 2013, the Company entered into an amended lease obligation to lease 24,335 square feet of office space in Atlanta, Georgia. The lease commenced upon taking possession of the space and ends in November 2022. The provisions of the lease provided for rent abatement for the first eight months of the lease term. Upon taking possession of the premises, the rent abatement and the unamortized balance of deferred rent associated with the previously leased premises were aggregated with the total expected rental payments and are being amortized on a straight-line basis over the term of the lease.

In fiscal 2014, the Company entered into a lease obligation to lease 10,350 square feet of office space in New York, New York. The lease commenced upon taking possession of the space and ends in November 2019. The lease agreement provided for rent abatement for the first two months of the lease term. Upon taking possession of the premises, the rent abatement was aggregated with the total expected rental payments, and is being amortized on a straight-line basis over the term of the lease.

The Company had capital leases to finance office equipment purchases that continued into the third quarter of fiscal 2017. The amortization expense of the leased equipment is included in depreciation expense. As of January 31, 2018 and 2017, the Company had capital lease obligations outstanding totaling zero and $91,000, respectively

Debt Issuance Costs

Costs related to the issuance of debt are capitalized and amortized to interest expense on a straight-line basis, which is not materially different from the effective interest method, over the term of the related debt. Deferred financing costs are presented on the Company’s consolidated balance sheets as a direct deduction from the carrying amount of the non-current portion of our term loan.

Impairment of Long-Lived Assets

The Company reviews the carrying value of long-lived assets whenever facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances are present which may indicate impairment is probable, the Company will prepare a projection of the undiscounted cash flows of the specific asset or asset group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair value.

Capitalized Software Development Costs

Software development costs associated with the planning and designing phase of software development, including coding and testing activities necessary to establish technological feasibility, are classified as research and development and are expensed as incurred. Once technological feasibility has been determined, a portion of the costs incurred in development, including coding, testing and quality assurance, are capitalized and subsequently reported at the lower of unamortized cost or net realizable value. The Company capitalized such costs, including interest, of $1,836,000 and $1,979,000 in fiscal 2017 and 2016, respectively. The Company assumed $350,000 in internally-developed software costs in 2016 through the acquisition of Opportune IT, which is described in Note 3 - Acquisitions and Divestitures.

Amortization for the Company's legacy software systems is provided on a solution-by-solution basis over the estimated economic life of the software, typically three to five years, using the straight-line method. Amortization commences when a solution is available for general release to clients. Acquired internally-developed software from acquisitions is amortized using the straight-line method.

Amortization expense on all internally-developed software was $2,113,000 and $2,771,000 in fiscal 2017 and 2016, respectively, and was included in the consolidated statements of operations as follows:



	Fiscal Year
Amortization expense on internally-developed software included in:	2017		2016
Cost of systems sales	$	1,914,000	$	2,495,000
Cost of software as a service	186,000		271,000
Cost of audit services	13,000		5,000
Total amortization expense on internally-developed software	$	2,113,000	$	2,771,000

Research and development expense was $5,352,000 and $7,454,000 in fiscal 2017 and 2016, respectively.

Fair Value of Financial Instruments

The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. The carrying amount of the Company’s long-term debt approximates fair value since the variable interest rates being paid on the amounts approximate the market interest rate. Long-term debt is classified as Level 2.

The table below provides information on our liabilities that are measured at fair value on a recurring basis:



	Total Fair Value		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
At January 31, 2018
Warrants liability (1)	$	—	$	—	$	—	$	—
Royalty liability (2)	2,469,000		—		—		2,469,000

At January 31, 2017
Warrants liability (1)	$	46,000	$	—	$	—	$	46,000
Royalty liability (2)	2,351,000		—		—		2,351,000

_______________

(1)

The initial fair value of warrants liability was determined by management with the assistance of an independent third-party valuation specialist, and by management thereafter. The Company issued common stock warrants in conjunction with the private placement investment, which were exercisable for up to 1,200,000 of the Company's common stock at an exercise price of $3.99 per share in whole or in part until February 16, 2018. See Note 4 - Derivative Liabilities and Note 14 - Private Placement Investment for further details. Changes in fair value of the warrants are recognized within miscellaneous (expense) income in the consolidated statements of operations.

(2)

The initial fair value of royalty liability was determined by management with the assistance of an independent third-party valuation specialist, and by management thereafter. The fair value of the royalty liability is determined based on the probability-weighted revenue scenarios for the Streamline Health® Clinical Analytics solution licensed from Montefiore Medical Center (discussed in Note 3 - Acquisitions and Divestitures). Fair value adjustments are included within miscellaneous (expense) income in the consolidated statements of operations.

Revenue Recognition

We derive revenue from the sale of internally-developed software, either by licensing for local installation or by software as a service (“SaaS”) delivery model, through our direct sales force or through third-party resellers. Licensed, locally-installed clients on a perpetual model utilize our support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization of the applications, as well as audit services provided to help clients review their internal coding audit processes. Additional revenues are also derived from reselling third-party software and hardware components.

We recognize revenue in accordance with Accounting Standards Codification (ASC) 985-605, Software-Revenue Recognition, ASC 605-25, Revenue Recognition — Multiple-Element Arrangements, and ASC 605-10-S99.

We commence revenue recognition when all of the following criteria have been met:


•	Persuasive evidence of an arrangement exists,


•	Delivery has occurred or services have been rendered,


•	The arrangement fees are fixed or determinable, and


•	Collectibility is reasonably assured.

If we determine that any of the above criteria have not been met, we will defer recognition of the revenue until all the criteria have been met. Maintenance and support and SaaS agreements are generally non-cancelable or contain significant penalties for early cancellation, although clients typically have the right to terminate their contracts for cause if we fail to perform material obligations. However, if non-standard acceptance periods, non-standard performance criteria or cancellation or right of refund terms are required, revenue is recognized upon the satisfaction of such criteria, as applicable.

Multiple Element Arrangements

We follow the accounting revenue guidance under Accounting Standards Update (ASU) 2009-13, Revenue Recognition (Topic 605), Multiple-Deliverable Revenue Arrangements — a consensus of the FASB Emerging Issues Task Force.

Terms used in evaluation are as follows:


•	VSOE (vendor-specific objective evidence) — the price at which an element is sold as a separate stand-alone transaction


•	TPE (third-party evidence) — the price of an element, charged by another company that is largely interchangeable in any particular transaction


•	ESP (estimated selling price) — our best estimate of the selling price of an element of the transaction

We follow accounting guidance for revenue recognition of multiple-element arrangements to determine whether such arrangements contain more than one unit of accounting. Multiple-element arrangements require the delivery or performance of multiple solutions, services and/or right-to-use assets. To qualify as a separate unit of accounting, the delivered item must have value to the client on a stand-alone basis. An item has stand-alone value to a client when it can be sold separately by any vendor or the client could resell the item on a stand-alone basis.

We have a defined pricing methodology for all elements of the arrangement and proper review of pricing to ensure adherence to our policies. Pricing decisions include cross-functional teams of senior management, which use market conditions, expected contribution margin, size of the client’s organization and pricing history for similar solutions when establishing the selling price.

Software as a Service

We use ESP to determine the value for a software-as-a-service arrangement as we cannot establish VSOE, and TPE is not a practical alternative due to differences in functionality from our competitors. Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution. Typically, revenue recognition commences once the client goes live on the system and is recognized ratably over the contract term.

Systems Sales

We use the residual method to determine fair value for proprietary perpetual software licenses sold in a multi-element arrangement. Under the residual method, we allocate the total value of the arrangement first to the undelivered elements based on their VSOE and allocate the remainder to the proprietary perpetual software license fees.

Typically, pricing decisions for proprietary software rely on the relative size and complexity of the client purchasing the solution. Third-party components are resold at prices based on a cost-plus margin analysis. The proprietary software and third-party components do not need any significant modification to achieve their intended use. When these revenues meet all criteria for revenue recognition, and are determined to be separate units of accounting, revenue is recognized. Typically, this is upon shipment of components or electronic download of software.

Maintenance and Support Services

The maintenance and support components are not essential to the functionality of the software, and clients renew maintenance contracts separately from software purchases at renewal rates materially similar to the initial rate charged for maintenance on the initial purchase of software. We use VSOE of fair value to determine fair value of maintenance and support services. Rates are set based on market rates for these types of services, and our rates are comparable to rates charged by our competitors, which are based on the knowledge of the marketplace by senior management. Generally, maintenance and support is calculated as a percentage of the list price of the proprietary license being purchased by a client. Clients have the option of purchasing additional annual maintenance service renewals each year for which rates are not materially different from the initial rate but typically include a nominal rate increase based on the consumer price index. Annual maintenance and support agreements entitle clients to technology support, version upgrades, bug fixes and service packs.

Term Licenses

We cannot establish VSOE fair value of the undelivered element in term license arrangements. However, as the only undelivered element is post-contract customer support, the entire fee is recognized ratably over the contract term. Typically, revenue recognition commences once the client goes live on the system. Similar to proprietary license sales, pricing decisions rely on the relative size of the client purchasing the solution.

Software-Based Solution Professional Services

Professional services components that are not essential to the functionality of the software, from time to time, are sold separately by us. Similar services are sold by other vendors, and clients can elect to perform similar services in-house. When professional services revenues are a separate unit of accounting, revenues are recognized as the services are performed. We use VSOE of fair value based on the hourly rate charged when services are sold separately, to determine fair value of professional services. We typically sell professional services on an hourly or fixed fee basis. We recognize hourly fees in revenue as services are rendered and fixed fee projects are recognized using the percentage-of-completion method or upon acceptance based on the contract language. We monitor projects to assure that the expected and historical rate earned remains within a reasonable range to the established selling price.

Professional services components related to SaaS are essential to the functionality of the software and are not considered a separate unit of accounting . We recognize revenue ratably over the life of the client, which approximates the duration of the initial contract term. We defer the associated direct costs for salaries and benefits expense for professional services contracts. These deferred costs will be amortized over the identical term as the associated revenues. As of January 31, 2018 and 2017, we had deferred costs of $471,000 and $500,000, respectively, net of accumulated amortization of $312,000 and $370,000, respectively. Amortization expense of these costs was $270,000 and $254,000 in fiscal 2017 and 2016, respectively.

Audit Services

Professional services relating to audit services are provided separately from software solutions, even those that may relate to coding and coding audit processes. These services are not essential to any software offering and are a separate unit of accounting. Accordingly, the revenues are recognized as the services are performed.

Concentrations

Financial instruments, which potentially expose the Company to concentrations of credit risk, consist primarily of accounts receivable. The Company’s accounts receivable are concentrated in the healthcare industry. However, the Company’s clients typically are well-established hospitals, medical facilities or major health information systems companies that resell the Company’s solutions that have good credit histories. Payments from clients have been received within normal time frames for the industry. However, some hospitals and medical facilities have experienced significant operating losses as a result of limits on third-party reimbursements from insurance companies and governmental entities and extended payment of receivables from these entities is not uncommon.

To date, the Company has relied on a limited number of clients and remarketing partners for a substantial portion of its total revenues. The Company expects that a significant portion of its future revenues will continue to be generated by a limited number of clients and its remarketing partners.

The Company currently buys all of its hardware and some major software components of its healthcare information systems from third-party vendors. Although there are a limited number of vendors capable of supplying these components, management believes that other suppliers could provide similar components on comparable terms.

Business Combinations

The assets acquired, liabilities assumed and contingent consideration are recorded at their fair value on the acquisition date with subsequent changes recognized in earnings. These estimates are inherently uncertain and are subject to refinement. Management develops estimates based on assumptions as a part of the purchase price allocation process to value the assets acquired and liabilities assumed as of the business combination date. As a result, the Company may recognize adjustments to provisional amounts of assets acquired or liabilities assumed in operating expenses in the reporting period in which the adjustments are determined.

The Company records acquisition and transaction related expenses in the period in which they are incurred. Acquisition and transaction-related expenses primarily consist of legal, banking, accounting and other advisory fees of third parties associated with potential acquisitions.

Goodwill and Intangible Assets

Goodwill and other intangible assets were recognized in conjunction with the Interpoint, Meta, CLG and Opportune IT acquisitions, as well as the Unibased acquisition (prior to divestiture of such assets). Identifiable intangible assets include purchased intangible assets with finite lives, which primarily consist of internally-developed software, client relationships, supplier agreements, non-compete agreements, customer contracts and license agreements. Finite-lived purchased intangible assets are amortized over their expected period of benefit, which generally ranges from one to 15 years, using the straight-line and undiscounted expected future cash flows methods. See Note 3 - Acquisitions and Divestitures for information on the sale of our Streamline Health® Patient Engagement suite of solutions in fiscal 2016, which the Company obtained in connection with its acquisition of Unibased in February 2014.

The Company assesses the useful lives and possible impairment of intangible assets when an event occurs that may trigger such a review. Factors considered important which could trigger a review include:


•	significant underperformance relative to historical or projected future operating results;


•	significant changes in the manner of use of the acquired assets or the strategy for the overall business;


•	identification of other impaired assets within a reporting unit;


•	disposition of a significant portion of an operating segment;


•	significant negative industry or economic trends;


•	significant decline in the Company's stock price for a sustained period; and


•	a decline in the market capitalization relative to the net book value.

Determining whether a triggering event has occurred involves significant judgment by the Company.

The Company assesses goodwill annually (as of November 1), or more frequently when events and circumstances, such as the ones mentioned above, occur indicating that the recorded goodwill may be impaired. During the years ended January 31, 2018 and 2017, the Company did not note any of the above qualitative factors, which would be considered a triggering event for impairment. In assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company assesses relevant events and circumstances that may impact the fair value and the carrying amount of a reporting unit. The identification of relevant events and circumstances and how these may impact a reporting unit's fair value or carrying amount involve significant judgments by management. These judgments include the consideration of macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, events which are specific to the Company and trends in the market price of the Company's common stock. Each factor is assessed to determine whether it impacts the impairment test positively or negatively, and the magnitude of any such impact.

The two-step goodwill impairment test requires the Company to identify its reporting units and to determine estimates of the fair values of those reporting units as of the impairment testing date. Reporting units are determined based on the organizational structure the entity has in place at the date of the impairment test. A reporting unit is an operating segment or component business unit with the following characteristics: (a) it has discrete financial information, (b) segment management regularly reviews its operating results (generally an operating segment has a segment manager who is directly accountable to and maintains regular contact with the chief operating decision maker to discuss operating activities, financial results, forecasts or plans for the segment), and (c) its economic characteristics are dissimilar from other units (this contemplates the nature of the products and services, the nature of the production process, the type or class of customer for the products and services and the methods used to distribute the products and services).

The Company determined that it has one operating segment and one reporting unit.

To conduct a quantitative two-step goodwill impairment test, the fair value of the reporting unit is first compared to its carrying value. If the reporting unit's carrying value exceeds its fair value, the Company performs the second step and records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value of its reporting unit using a blend of market and income approaches. The market approach consists of two separate methods, including reference to the Company's market capitalization, as well as the guideline publicly traded company method. The market capitalization valuation method is based on an analysis of the Company's stock price on and around the testing date, plus a control premium. The guideline publicly traded company method was made by reference to a list of publicly traded software companies providing services to healthcare organizations, as determined by management. The market value of common equity for each comparable company was derived by multiplying the price per share on the testing date by the total common shares outstanding, plus a control premium. Selected valuation multiples are then determined and applied to appropriate financial statistics based on the Company's historical and forecasted results. The Company estimates the fair value of its reporting unit using the income approach, via discounted cash flow valuation models which include, but are not limited to, assumptions such as a “risk-free” rate of return on an investment, the weighted average cost of capital of a market participant and future revenue, operating margin, working capital and capital expenditure trends. Determining the fair value of reporting unit and goodwill includes significant judgment by management, and different judgments could yield different results.

The Company performed its annual assessment of goodwill during the fourth quarter of fiscal 2017, using the two-step approach described above. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit with its carrying amount, including goodwill. Based on the analysis performed for step one, the fair value of the reporting unit exceeded the carrying amount of the reporting unit, including goodwill, and, therefore, an impairment loss was not recognized. As the Company passed step one of the analysis, step two was not required.

Severances

From time to time, we will enter into termination agreements with associates that may include supplemental cash payments, as well as contributions to health and other benefits for a specific time period subsequent to termination. In fiscal 2017 and 2016, we incurred $58,000 and $360,000 in severance expenses, respectively. At January 31, 2018 and 2017, we had accrued for zero and $9,000 in severances, respectively.

Equity Awards

The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite service period. The Company incurred total annual compensation expense related to stock-based awards of $1,109,000 and $1,787,000 in fiscal 2017 and 2016, respectively.

The fair value of the stock options granted in fiscal 2017 and 2016 was estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. Further, the forfeiture rate impacts the amount of aggregate compensation. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor, expected term and forfeiture rates). Future grants of equity awards accounted for as stock-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards.

The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market close price per share on the grant date. The Company expenses the compensation cost of these awards as the restriction period lapses, which is typically a one-year service period to the Company. In fiscal 2017 and 2016, 32,033 and 8,241 shares of common stock were surrendered to the Company to satisfy tax withholding obligations totaling $42,000 and $12,000, respectively, in connection with the vesting of restricted stock awards. Shares surrendered by the restricted stock award recipients in accordance with the applicable plan are deemed canceled, and therefore are not available to be reissued. The Company awarded 220,337 and 828,225 shares of restricted stock to officers and directors of the Company in fiscal 2017 and 2016, respectively.

Common Stock Warrants

As of January 31, 2018 and 2017, the fair value of the common stock warrants was computed using the Black-Scholes option pricing model based on assumptions regarding annual volatility, risk-free rate, dividend yield and expected life. The model also includes assumptions to account for anti-dilutive provisions within the warrant agreement. The warrants expired on February 16, 2018.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. See Note 8 - Income Taxes for further details.

The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. At January 31, 2018, the Company believes it has appropriately accounted for any uncertain tax positions. The Company has recorded $286,000 and $263,000 in reserves for uncertain tax positions and corresponding interest and penalties, respectively, as of January 31, 2018 and January 31, 2017.

Net Loss Per Common Share

The Company presents basic and diluted earnings per share (“EPS”) data for its common stock. Basic EPS is calculated by dividing the net loss attributable to common stockholders of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted EPS is calculated based on the profit or loss attributable to common stockholders and the weighted average number of shares of common stock outstanding adjusted for the effects of all potential dilutive common stock issuances related to options, unvested restricted stock, warrants and convertible preferred stock. Potential common stock dilution related to outstanding stock options, unvested restricted stock and warrants is determined using the treasury stock method, while potential common stock dilution related to Series A Convertible Preferred Stock is determined using the “if converted” method.

The Company's unvested restricted stock awards and Series A Convertible Preferred Stock are considered participating securities under ASC 260, Earnings Per Share, which means the security may participate in undistributed earnings with common stock. The Company's unvested restricted stock awards are considered participating securities because they entitle holders to non-forfeitable rights to dividends or dividend equivalents during the vesting term. The holders of the Series A Convertible Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of common stock were to receive dividends, other than dividends in the form of common stock. In accordance with ASC 260, a company is required to use the two-class method when computing EPS when a company has a security that qualifies as a “participating security.” The two-class method is an earnings allocation formula that determines EPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding for the period. Diluted EPS for the Company's common stock is computed using the more dilutive of the two-class method or the if-converted method.

In accordance with ASC 260, securities are deemed not to be participating in losses if there is no obligation to fund such losses. For the years ended January 31, 2018 and 2017, the unvested restricted stock awards and the Series A Preferred Stock were deemed not to be participating since there was a net loss from operations. As of both January 31, 2018 and 2017, there were 2,949,995 shares of preferred stock outstanding, each share being convertible into one share of the Company's common stock. For the years ended January 31, 2018 and 2017, 293,568 and 377,135, respectively, unvested restricted shares of common stock were excluded from the diluted EPS calculation as their effect would have been anti-dilutive.

The following is the calculation of the basic and diluted net loss per share of common stock:



	Fiscal Year
	2017			2016
Net loss	$	(3,099,214	)	$	(5,161,566	)
Less: deemed dividends on Series A Preferred Stock	—			(875,935		)
Net loss attributable to common shareholders	$	(3,099,214	)	$	(6,037,501	)
Weighted average shares outstanding - Basic	19,876,383			19,528,341
Stock options and restricted stock	—			—
Weighted average shares outstanding - Diluted	19,876,383			19,528,341
Basic net loss per share of common stock	$	(0.16	)	$	(0.31	)
Diluted net loss per share of common stock	$	(0.16	)	$	(0.31	)

Diluted net loss per share excludes the effect of 2,173,156 and 2,100,480 outstanding stock options in fiscal 2017 and 2016, respectively. The inclusion of these shares would have been anti-dilutive. For fiscal 2017 and 2016, the outstanding common stock warrants of 1,400,000 would have an anti-dilutive effect if included in Diluted EPS and, therefore, were not included in the calculation.

Loss Contingencies

We are subject to the possibility of various loss contingencies arising in the course of business. We consider the likelihood of the loss or impairment of an asset or the incurrence of a liability as well as our ability to reasonably estimate the amount of loss in determining loss contingencies. An estimated loss contingency is accrued when it is probable that a liability has been incurred or an asset has been impaired and the amount of loss can be reasonably estimated. We regularly evaluate current information available to us to determine whether to accrue for a loss contingency and adjust any previous accrual.

Recent Accounting Pronouncements

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 defines a five-step process to achieve this principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2016, the FASB delayed the effective date by one year and the guidance became effective for us on February 1, 2018. The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application as an adjustment to retained earnings (modified retrospective method). We have decided to adopt the standard effective February 1, 2018 using the modified retrospective method.

We have completed our assessment of our systems, available data and processes that will be affected by the implementation of this new revenue recognition guidance. The Company’s formal accounting policies have been established. As a result of the implementation of this standard, the Company expects to record an adjustment to increase retained earnings as of February 1, 2018. At this time, we estimate this increase to be approximately $1.4 million, related primarily to the timing of revenue. The most significant impact relates to our accounting for term software license revenue. We expect revenue related to SaaS-based offerings, hardware sales, maintenance and support, and audit services to remain substantially unchanged. For arrangements which include both software license and maintenance and support components, we expect to recognize the revenue attributed to license upfront at a point in time rather than over the term of the contract. We also expect to recognize license revenues upfront rather than be restricted to payment amounts due under extended payment term contracts as required under the previous guidance. Due to the complexity of certain of our license contracts, the actual revenue license recognition treatment will be dependent on contract-specific terms and may vary in some instances from upfront recognition and be delayed until acceptance from the client is obtained and documented. Additionally, the new revenue recognition guidance requires the capitalization of all incremental costs of obtaining a contract with a customer that an entity expects to recover. We currently already capitalize sales commissions associated with new and renewal contracts. As part of our implementation efforts, we did not identify any other costs that would be eligible for capitalization under the new guidance. As result, we do not expect to record any deferral for such costs upon adoption of the new guidance on February 1, 2018.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The ASU is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The update will be effective for us on February 1, 2019. Early adoption of the update is permitted. We are currently evaluating the impact of the adoption of this update on our consolidated financial statements and related disclosures.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, to clarify how certain cash receipts and cash payments should be presented and classified in the statement of cash flows. The ASU should be applied using a retrospective transition method to each period presented. The standard became effective for us on February 1, 2018. Early adoption of this update is permitted. We are currently evaluating the impact of the adoption of this new standard on our consolidated financial statements and related disclosures.

In January 2017, the FASB issued ASU 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, to clarify the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard became effective for us on February 1, 2018. We do not expect that the adoption of this ASU will have a significant impact on our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which removes Step 2 from the goodwill impairment test. The standard will be effective for us on February 1, 2020. Early adoption of this update is permitted. We do not expect that the adoption of this ASU will have a significant impact on our consolidated financial statements.

In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718), Scope of Modification Accounting, to clarify which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The update became effective for us on February 1, 2018. We do not expect that the adoption of this ASU will have a significant impact on our consolidated financial statements.

Acquisitions and Divestitures

12 Months Ended

Jan. 31, 2018

Business Combinations [Abstract]

ACQUISITIONS AND DIVESTITURES

Acquisition of Interpoint Partners, LLC

On December 7, 2011, the Company completed the acquisition of substantially all of the assets of Interpoint Partners, LLC (“Interpoint”) for a total initial purchase price of $5,124,000, consisting of cash of $2,124,000 and issuance of a convertible subordinated note for $3,000,000. The note was converted into 1,529,729 shares of common stock on June 15, 2012 at a price of $2.00 per share. All consideration was paid prior to fiscal year 2016.

Acquisition of Meta Health Technology, Inc.

On August 16, 2012, the Company acquired substantially all of the outstanding stock of Meta Health Technology, Inc., a New York corporation (“Meta”) for a total purchase price of approximately $14,790,000, consisting of cash payment of $13,288,000 and the issuance of 393,086 shares of our common stock at an agreed upon price of $4.07 per share. As of October 31, 2012 the Company had acquired 100% of Meta’s outstanding shares, and the Company merged Meta with and into the Company on January 30, 2014. All consideration was paid prior to fiscal year 2016.

Acquisition of a Montefiore Medical Center Solution

On October 25, 2013, we entered into a Software License and Royalty Agreement (the “Royalty Agreement”) with Montefiore Medical Center (“Montefiore”) pursuant to which it entered into an agreement for an exclusive, worldwide 15-year license of Montefiore’s proprietary clinical analytics platform solution, Clinical Looking Glass® (“CLG”), now known as our Clinical Analytics solution. In addition, Montefiore assigned to us the existing license agreement with a customer using CLG. As consideration under the Royalty Agreement, Streamline paid Montefiore a one-time initial base royalty fee of $3,000,000, and we are obligated to pay on-going quarterly royalty amounts related to future sublicensing of CLG by Streamline. Additionally, Streamline has committed that Montefiore will receive at least an additional $3,000,000 of on-going royalty payments within the first six and one-half years of the license term. As of January 31, 2018 and 2017, the present value of this royalty liability was $2,469,000 and $2,351,000, respectively.

Acquisition of Unibased Systems Architecture, Inc. and Related Divestiture

On February 3, 2014, we completed the acquisition of Unibased Systems Architecture, Inc. (“Unibased”), a provider of patient access solutions, including enterprise scheduling and surgery management software, for healthcare organizations throughout the United States, pursuant to an Agreement and Plan of Merger dated January 16, 2014 (the “Merger Agreement”). The total purchase price for Unibased was $6,500,000, subject to net working capital and other customary adjustments.

On December 1, 2016, we received a cash payment of $2,000,000 for the sale of our Streamline Health® Patient Engagement suite of solutions, which is based upon the legacy ForSite2020 solution acquired from Unibased in February 2014. As a result, we recognized a gain on sale of business of $238,000 in fiscal 2016, which represents the amount by which the sale proceeds exceeded net assets associated with Patient Engagement operations, including accounts receivable, intangible assets and deferred revenue. We used the proceeds to make two prepayments of $500,000 on our term loan with Wells Fargo, one in the fourth quarter of fiscal 2016 and another in the second quarter of fiscal 2017.

Acquisition of Opportune IT Healthcare Solutions, Inc.

On September 8, 2016, we completed the acquisition of substantially all of the assets of Opportune IT Healthcare Solutions, Inc. (“Opportune IT”), a provider of coding compliance, recovery audit contractor consulting and ICD-10 readiness and training services to hospitals, physicians and medical groups. As consideration under the asset purchase agreement, we made a cash payment for the total purchase price of $1,400,000. The Company also assumed certain current operating liabilities of Opportune IT. The purchase price has been allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date as follows:



	Balance at September 8, 2016
Assets purchased:
Accounts and contracts receivable	$	792,000
Other assets	32,000
Internally-developed software	350,000
Intangible assets	650,000
Total assets purchased	1,824,000
Liabilities assumed:
Accounts payable and accrued liabilities	424,000
Net assets acquired	$	1,400,000
Cash paid	$	1,400,000

The operating results of Opportune IT are not material for purposes of proforma disclosure.

Derivative Liabilities	12 Months Ended
Derivative Liabilities	Jan. 31, 2018
Other Liabilities Disclosure [Abstract]
DERIVATIVE LIABILITIES	DERIVATIVE LIABILITIES As discussed further in Note 14 - Private Placement Investment, in conjunction with the 2012 private placement investment, the Company issued common stock warrants exercisable for up to 1,200,000 shares of common stock at an exercise price of $3.99 per share until February 16, 2018. The warrants were initially classified in stockholders' equity as additional paid-in capital at the allocated amount, net of allocated transaction costs of $1,425,000. Effective October 31, 2012, upon stockholder approval of anti-dilution provisions that reset the warrants’ exercise price if a dilutive issuance occurs, the warrants were reclassified as non-current derivative liabilities. The fair value of the warrants was $4,139,000 at October 31, 2012, with the difference between the fair value and carrying value recorded to additional paid-in capital. Effective as of the reclassification as derivative liabilities, the warrants are re-valued at each reporting date, with changes in fair value recognized in earnings each reporting period as a credit or charge to miscellaneous income (expense). The fair value of the warrants at January 31, 2018 and 2017 was zero and $46,000, respectively. The change in fiscal 2017 and 2016 reflects $46,000 and $159,000, respectively, of miscellaneous income recognized in the consolidated statements of operations as a result of decreases in the fair value of the warrants. The estimated fair value of the warrants liabilities as of January 31, 2017 was computed using the Black-Scholes option pricing model based on the following assumptions: annual volatility of 62.6%, risk-free rate of 0.5%, dividend yield of 0.0% and expected life of one year. The estimated fair value of the warrants liabilities as of January 31, 2018 was computed using the Black-Scholes option pricing model based on the following assumptions: annual volatility of 57.4%, risk-free rate of 0.0%, dividend yield of 0.0% and expected life of zero years.

Operating Leases

12 Months Ended

Jan. 31, 2018

Leases [Abstract]

OPERATING LEASES

The Company rents office space and equipment under non-cancelable operating leases that expire at various times through fiscal year 2022. Future minimum lease payments under non-cancelable operating leases for the next five fiscal years are as follows:



	Facilities		Equipment		Fiscal Year Totals
2018	$	1,039,000	$	11,000	$	1,050,000
2019	967,000		11,000		978,000
2020	504,000		11,000		515,000
2021	519,000		2,000		521,000
2022	445,000		—		445,000
Total	$	3,474,000	$	35,000	$	3,509,000

Rent and leasing expense for facilities and equipment was $1,234,000 and $1,271,000 for fiscal years 2017 and 2016, respectively.

Debt

12 Months Ended

Jan. 31, 2018

Debt Disclosure [Abstract]

DEBT

Term Loan and Line of Credit

On November 21, 2014, we entered into a Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, N.A., as administrative agent, and other lender parties thereto. Pursuant to the Credit Agreement, the lenders agreed to provide a $10,000,000 senior term loan and a $5,000,000 revolving line of credit to our primary operating subsidiary. Amounts outstanding under the Credit Agreement bear interest at either LIBOR or the base rate, as elected by the Company, plus an applicable margin. Subject to the Company’s leverage ratio, under the terms of the original Credit Agreement, the applicable LIBOR rate margin varied from 4.25% to 5.25%, and the applicable base rate margin varied from 3.25% to 4.25%. Pursuant to the terms of the amendment to the Credit Agreement entered into as of April 15, 2015, the applicable LIBOR rate margin was amended to vary from 4.25% to 6.25%, and the applicable base rate margin was amended to vary from 3.25% to 5.25%. The term loan and line of credit mature on November 21, 2019 and provide support for working capital, capital expenditures and other general corporate purposes, including permitted acquisitions. The outstanding senior term loan is secured by substantially all of our assets. The senior term loan principal balance is payable in quarterly installments, which started in March 2015 and will continue through the maturity date, with the full remaining unpaid principal balance due at maturity. In November 2014, the Company repaid indebtedness under its prior credit facility using approximately $7,400,000 of the proceeds provided by the term loan. The prior credit facility with Fifth Third Bank was terminated concurrent with the entry into the Credit Agreement. Financing costs of $355,000 associated with the new credit facility are being amortized over its term on a straight-line basis, which is not materially different from the effective interest method.

The Credit Agreement includes customary financial covenants, including the requirements that the Company maintain minimum liquidity and achieve certain minimum EBITDA levels (as defined in the Credit Agreement). In addition, the Credit Agreement prohibits the Company from paying dividends on the common and preferred stock. Pursuant to the terms of the third amendment to the Credit Agreement entered into as of June 19, 2017, the Company is required to maintain minimum liquidity of at least (i) $5,000,000 through January 31, 2018, (ii) $4,000,000 from February 1, 2018 through and including January 31, 2019, and (iii) $3,000,000 from February 1, 2019 through and including the maturity date of the credit facility.

The following table shows our minimum trailing four quarter period EBITDA covenant thresholds, as modified by the third amendment to the Credit Agreement:



For the four-quarter period ending	Minimum EBITDA
July 31, 2017	$	(1,250,000	)
October 31, 2017	(1,000,000		)
January 31, 2018	(700,000		)
April 30, 2018	(35,869		)
July 31, 2018	414,953
October 31, 2018	1,080,126
January 31, 2019	1,634,130
April 30, 2019	1,842,610
July 31, 2019	2,657,362
October 31, 2019 and each fiscal quarter thereafter	3,613,810

The Company was in compliance with the applicable financial loan covenants at January 31, 2018.

As of January 31, 2018, the Company had no outstanding borrowings under the revolving line of credit, and had accrued $18,000 in unused line fees. Based upon the borrowing base formula set forth in the Credit Agreement, as of January 31, 2018, the Company had access to the full amount of the $5,000,000 revolving line of credit.

Outstanding principal balances on debt consisted of the following at:



	January 31, 2018			January 31, 2017
Senior term loan	$	4,626,000		$	5,738,000
Capital lease	—			91,000
Total	4,626,000			5,829,000
Deferred financing cost	(128,000		)	(199,000		)
	4,498,000			5,630,000
Less: Current portion	(597,000		)	(747,000		)
Non-current portion of long-term debt	$	3,901,000		$	4,883,000

In May 2016, as a result of excess cash flows achieved as of January 31, 2016 and as required pursuant to the mandatory prepayment provisions of the Credit Agreement, we made a $1,738,000 payment of principal towards the term loan with Wells Fargo. We used the proceeds from the sale of our Patient Engagement suite of solutions to make two prepayments on our term loan with Wells Fargo, one in December 2016 and one in June 2017, each in the amount of $500,000. As a result of these prepayments, the schedule of future principal payments was revised to reduce each future principal payment on a pro rata basis.

Future principal repayments of debt consisted of the following at January 31, 2018:



	Senior Term Loan (1)
2018	$	597,000
2019	4,029,000
Total repayments	$	4,626,000

_______________

(1) Term loan balance on the consolidated balance sheet is reported net of deferred financing costs of $128,000.

Goodwill and Intangible Assets

12 Months Ended

Jan. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

The goodwill activity is summarized as follows:



	Goodwill
Balance at January 31, 2016	$	16,185,000
Adjustments to goodwill related to sale of business during fiscal 2016	(648,000		)
Balance at January 31, 2017 and January 31, 2018	$	15,537,000

Intangible assets, net, consist of the following:



	January 31, 2018
	Estimated Useful Life	Gross Assets		Accumulated Amortization		Net Assets
Finite-lived assets:
Client relationships	5-15 years	$	5,805,000	$	3,308,000	$	2,497,000
Covenants not to compete	0.5-15 years	986,000		823,000		163,000
Supplier agreements	5 years	1,582,000		1,582,000		—
License agreement	15 years	4,431,000		1,256,000		3,175,000
Total		$	12,804,000	$	6,969,000	$	5,835,000



	January 31, 2017
	Estimated Useful Life	Gross Assets		Accumulated Amortization		Net Assets
Finite-lived assets:
Client relationships	5-15 years	5,805,000		2,692,000		3,113,000
Covenants not to compete	0.5-15 years	986,000		744,000		242,000
Supplier agreements	5 years	1,582,000		1,411,000		171,000
License agreement	15 years	4,431,000		960,000		3,471,000
Total		$	12,804,000	$	5,807,000	$	6,997,000

Amortization over the next five fiscal years for intangible assets is estimated as follows:



	Annual Amortization Expense
2018	$	937,000
2019	885,000
2020	823,000
2021	786,000
2022	500,000
Thereafter	1,904,000
Total	$	5,835,000

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Income Taxes

12 Months Ended

Jan. 31, 2018

Income Tax Disclosure [Abstract]

INCOME TAXES

Income taxes consist of the following:



	Fiscal Year
	2017			2016
Current tax (expense) benefit:
Federal	$	—		$	15,000
State	(11,573		)	(2,976		)
Total current provision	(11,573		)	12,024
Deferred tax benefit:
Federal	95,403			—
State	—			—
Total Deferred tax benefit	95,403			—
Current and deferred tax benefit	$	83,830		$	12,024

The income tax benefit differs from the amount computed using the federal statutory income tax rate of 32.9 percent as follows:



	Fiscal Year
	2017			2016
Federal tax benefit at statutory rate of 32.9 percent	$	1,047,221		$	1,771,675
State and local taxes, net of federal benefit (expense)	195,117			84,402
Change in valuation allowance	4,504,875			(2,134,096		)
Permanent items:
Incentive stock options	(112,349		)	(361,245		)
Change in fair value of warrants liability	15,197			54,033
Goodwill basis difference recognized upon asset sale	—			(220,112		)
Section 162(m) disallowance	—			(22,647		)
Other	(24,673		)	(23,272		)
Reserve for uncertain tax position	(18,509		)	(262,525		)
R&D Credit (Federal)	219,305			1,045,453
R&D Credit (State)	(129,111		)	267,172
Tax Cuts and Jobs Act	(5,827,034		)	—
Other	213,791			(186,814		)
Income tax benefit	$	83,830		$	12,024

The Company provides deferred income taxes for temporary differences between assets and liabilities recognized for financial reporting and income tax purposes. The income tax effects of these temporary differences and credits are as follows:



	January 31,
	2018			2017
Deferred tax assets:
Allowance for doubtful accounts	$	91,360		$	72,886
Deferred revenue	154,574			282,112
Accruals	71,286			120,165
Net operating loss carryforwards	10,617,120			15,141,861
Stock compensation expense	235,920			501,120
Property and equipment	108,537			132,934
AMT credit	—			102,144
R&D credit	1,144,058			1,050,100
Other	116,603			106,833
Total deferred tax assets	12,539,458			17,510,155
Valuation allowance	(11,812,860		)	(16,318,124		)
Net deferred tax assets	726,598			1,192,031
Deferred tax liabilities:
Definite-lived intangible assets	(726,598		)	(1,192,031		)
Total deferred tax liabilities	(726,598		)	(1,192,031		)
Net deferred tax liabilities	$	—		$	—

At January 31, 2018, the Company had U.S. federal net operating loss carry forwards of $45,973,000, which expire at various dates through fiscal 2037. The Company also had state net operating loss carry forwards of $18,230,000, which expire through fiscal 2037. Federal and state R&D credit carry forwards will expire through fiscal 2037 and 2027, respectively.

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company established a valuation allowance of $11,813,000 and $16,318,000 at January 31, 2018 and 2017, respectively. The decrease in the valuation allowance of $4,505,000 was driven primarily by the federal tax rate change from the passage of the Tax Cuts and Jobs Act.

The Company and its subsidiary are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2013. All material state and local income tax matters have been concluded for years through January 31, 2012. The Company is no longer subject to IRS examination for periods prior to the tax year ended January 31, 2013; however, carryforward losses that were generated prior to the tax year ended January 31, 2013 may still be adjusted by the IRS if they are used in a future period.

The Company has recorded a reserve, including interest and penalties, for uncertain tax positions of $286,000 and $263,000 as of January 31, 2018 and 2017, respectively. As of January 31, 2018 and 2017, the Company had no accrued interest and penalties associated with unrecognized tax benefits.

A reconciliation of the beginning and ending amounts of gross unrecognized tax benefits (excluding interest and penalties) is as follows:



	2017			2016
Beginning of fiscal year	$	290,000		$	—
Additions for tax positions for the current year	62,000			59,000
Additions for tax positions of prior years	3,000			231,000
Subtractions for tax positions of prior years	(60,000		)	—
End of fiscal year	$	295,000		$	290,000

Impact of the Tax Cuts and Jobs Act

The Tax Act was signed into law on December 22, 2017. Among other things, the Tax Act reduces the U.S. federal corporate tax rate from 34.0 percent to 21.0 percent effective January 1, 2018 and allows for 100 percent expensing of certain fixed assets placed in service after September 27, 2017.

On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of U.S. GAAP in situations where a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to finalize the calculations for certain income tax effects of the Tax Cuts and Jobs Act. In accordance with SAB 118, the Company has determined that the net tax expense of $5.8 million recorded in connection with the tax effect of the Tax Act is a provisional amount and a reasonable estimate as of January 31, 2018. Additional work is necessary to finalize the calculation for certain income tax effects of the Tax Cuts and Jobs Act, which we expect to complete with the filing of our 2017 U.S. federal income tax return.

Employee Stock Purchase Plan	12 Months Ended
Employee Stock Purchase Plan	Jan. 31, 2018
Employee Stock Ownership Plan (ESOP), Shares in ESOP [Abstract]
EMPLOYEE STOCK PURCHASE PLAN	EMPLOYEE STOCK PURCHASE PLAN The Company has an Employee Stock Purchase Plan under which associates may purchase up to 1,000,000 shares of common stock. Under the plan, eligible associates may elect to contribute, through payroll deductions, up to 10% of their base pay to a trust during any plan year, i.e., January 1 through December 31 of the same year. Semi-annually, typically in January and July of each year, the plan issues, for the benefit of the employees, shares of common stock at the lesser of (a) 85% of the fair market value of the common stock on the first day of the vesting period (January 1 or July 1), or (b) 85% of the fair market value of the common stock on the last day of the vesting period (June 30 or December 31 of the same year). At January 31, 2018, 455,265 shares remain that can be purchased under the plan. The Company recognized compensation expense of $19,000 and $5,000 for fiscal years 2017 and 2016, respectively, under this plan. During fiscal 2017, 21,234 shares were purchased at the price of $0.98 per share and 26,048 shares were purchased at the price of $0.91 per share; during fiscal 2016, 25,617 shares were purchased at the price of $1.02 per share. The cash received for shares purchased from the plan was $45,000 and $26,000 in fiscal 2017 and 2016, respectively. The purchase price at June 30, 2018 will be 85% of the lower of (a) the closing price on January 2, 2018 ($1.68) or (b) the closing price on June 30, 2018.

Stock-Based Compensation

12 Months Ended

Jan. 31, 2018

Employee Stock Ownership Plan (ESOP), Shares in ESOP [Abstract]

STOCK-BASED COMPENSATION

Stock Option Plans

The Company’s Second Amended and Restated 2013 Stock Incentive Plan (the “2013 Plan”) replaced the 2005 Incentive Compensation Plan (the “2005 Plan”). Under these plans, the Company is authorized to issue equity awards (stock options, stock appreciation rights or “SARs”, and restricted stock) to directors and associates of the Company. Outstanding awards under the 2005 Plan continue to be governed by the terms of the 2005 Plan until exercised, expired or otherwise terminated or canceled, but no further equity awards are allowed to be granted under the 2005 Plan. Under the 2013 Plan, the Company is authorized to issue a number of shares not to exceed (i) 2,300,000 plus (ii) the number of shares remaining available for issuance under the 2005 Plan as of the date the 2005 Plan was replaced, plus (iii) the number of shares that become available under the 2005 Plan pursuant to forfeiture, termination, lapse, or satisfaction of a 2005 Plan award in cash or property other than shares of common stock. The options granted under the 2013 Plan and 2005 Plan have terms of ten years or less, and typically vest and become fully exercisable ratably over three years of continuous service to the Company from the date of grant. At January 31, 2018 and 2017, options to purchase 1,873,156 and 1,800,480 shares of the Company’s common stock, respectively, have been granted and are outstanding. There are no SARs outstanding.

In fiscal 2016 and 2014, inducement grants were approved by the Company’s Board of Directors pursuant to NASDAQ Marketplace Rule 5635(c)(4). The terms of the grants were nearly identical to the terms and conditions of the Company’s stock incentive plans in effect at the time of each inducement grant. For the year ended January 31, 2018, with regard to inducement grants, no stock options were issued, no options expired, no options were forfeited and no stock options were exercised. For the year ended January 31, 2017, with regard to inducement grants, 75,000 stock options were issued, no options expired, no options were forfeited and no stock options were exercised. As of both January 31, 2018 and 2017, there were 300,000 options outstanding.

Please see “Restricted Stock” section for information on the restricted shares.

A summary of stock option activity follows:



	Options		Weighted Average Exercise Price			Remaining Life in Years	Aggregate intrinsic value
Outstanding as of February 1, 2017	2,100,480		$	4.16
Granted	265,000		1.17
Exercised	—		—
Expired	(133,323	)	4.73
Forfeited	(59,001	)	2.24
Outstanding as of January 31, 2018	2,173,156		$	3.42	(1)	7.11	$	3,868,218
Exercisable as of January 31, 2018	1,626,404		$	3.98	(2)	6.67	$	2,894,999
Vested or expected to vest as of January 31, 2018	2,102,078		$	3.47		7.07	$	3,741,699

_______________


(1)	The exercise prices range from $1.06 to $8.10, of which 677,499 shares are between $1.06 and $2.00 per share, 525,240 shares are between $2.19 and $4.00 per share, and 970,417 shares are between $4.02 and $8.10 per share.


(2)	The exercise prices range from $1.18 to $8.10, of which 254,332 shares are between $1.18 and $2.00 per share, 442,155 shares are between $2.19 and $4.00 per share, and 929,917 shares are between $4.02 and $8.10 per share.

For fiscal 2017 and 2016, the weighted average grant date fair value of options granted during the year was $0.65 and $0.79, respectively, and the total intrinsic value of options exercised during the year was zero for both fiscal years.

The fiscal 2017 and 2016 stock-based compensation was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions for each fiscal year:



	2017		2016
Expected life	6 years		6 years
Risk-free interest rate	2.65	%	2.10	%
Weighted average volatility factor	0.65		0.58
Dividend yield	—		—
Forfeiture rate	13	%	22	%

At January 31, 2018, there was $320,000 of unrecognized compensation cost related to non-vested stock-option awards. That cost is expected to be recognized over a remaining weighted average period of 1.2 years. The expense associated with stock option awards was $563,000 and $1,321,000, respectively, for fiscal 2017 and 2016. Cash received from the exercise of options was zero in both fiscal 2017 and 2016. Cash received from purchases pursuant to the Employee Stock Purchase Plan was $45,000 and $26,000, respectively, in fiscal 2017 and 2016.

The 2005 Plan and the 2013 Plan contain change in control provisions whereby any outstanding equity awards under the plans subject to vesting, which have not fully vested as of the date of the change in control, shall automatically vest and become immediately exercisable. One of the change in control provisions is deemed to occur if there is a change in beneficial ownership, or authority to vote, directly or indirectly, of securities representing 20% or more of the total of all of the Company’s then-outstanding voting securities, unless through a transaction arranged by or consummated with the prior approval of the Board of Directors. Other change in control provisions relate to mergers and acquisitions or a determination of change in control by the Company’s Board of Directors.

Restricted Stock

The Company is authorized to grant restricted stock awards to associates and directors under the 2013 Plan. The Company has also issued restricted stock as inducement grants to certain new employees. The restrictions on the shares granted generally lapse over a one- to four-year term of continuous employment from the date of grant. The grant date fair value per share of restricted stock, which is based on the closing price of our common stock on the grant date, is expensed on a straight-line basis as the restriction period lapses. The shares represented by restricted stock awards are considered outstanding at the grant date, as the recipients are entitled to voting rights. A summary of restricted stock award activity for fiscal 2017 and 2016 is presented below:



	Non-vested Number of Shares		Weighted Average Grant Date Fair Value
Non-vested balance at January 31, 2016	112,380		$	2.62
Granted	858,225		1.59
Vested	(112,380	)	2.56
Forfeited	—		—
Non-vested balance at January 31, 2017	858,225		$	1.59
Granted	295,337		1.17
Vested	(331,975	)	1.47
Forfeited	—		—
Non-vested balance at January 31, 2018	821,587		$	1.59

At January 31, 2018, there was $741,000 of unrecognized compensation cost related to restricted stock awards. That cost is expected to be recognized over a remaining period of 1.3 years.

The expense associated with restricted stock awards was $546,000 and $466,000, respectively, for fiscal 2017 and 2016.

Private Placement Investment

12 Months Ended

Jan. 31, 2018

Equity [Abstract]

PRIVATE PLACEMENT INVESTMENT

On August 16, 2012, the Company completed a $12,000,000 private placement investment (“private placement investment”) with affiliated funds and accounts of Great Point Partners, LLC, Noro-Moseley Partners VI, L.P., and another investor. The investment consisted of the following instruments: issuance of 2,416,785 shares of a new Series A 0% Redeemable Convertible Preferred Stock (“Series A Preferred Stock”) at $3.00 per share, common stock warrants (“warrants”) exercisable for up to 1,200,000 shares of the Company's common stock at an exercise price of $3.99 per share and convertible subordinated notes payable in the aggregate principal amount of $5,699,577, which upon stockholder approval, converted into 1,583,210 shares of Series A Preferred Stock. The proceeds were allocated among the instruments based on their relative fair values as follows:



	Fair Value at August 16, 2012		Proceeds Allocation at August 16, 2012
Instruments:
Series A Preferred Stock	$	9,907,820	$	6,546,146	(1)
Convertible subordinated notes payable	5,699,577		3,765,738		(2)
Warrants	2,856,000		1,688,116		(3)
Total investment	$	18,463,397	$	12,000,000

_______________

(1)

The Series A Preferred Stock convert on a 1:1 basis into common stock, but differ in value from common stock due to the downside protection relative to common stock in the event the Company liquidates, and the downside protection, if, after four years, the holder has not converted and the stock is below $3.00. The fair value of Series A Preferred Stock was determined using a Monte-Carlo simulation following a Geometric Brownian Motion, using the following assumptions: annual volatility of 75%, risk-free rate of 0.9% and dividend yield of 0.0%. The model also utilized the following assumptions to account for the conditions within the agreement: after four years, if the simulated common stock price fell below a price of $3.00 per share, the convertible preferred stock would automatically convert to common stock on a 1:1 basis moving forward at a price of $3.00 per share and a forced conversion if the simulated stock price exceeded $8.00 per share.

(2)

The fair value of convertible subordinated notes payable was determined based on its current yield as compared to that of those currently outstanding in the marketplace. Management reviewed the convertible note agreement and determined that the note's interest rate is a reasonable representative of a market rate; therefore the face or principal amount of the loan is a reasonable estimate of its fair value.

(3)

The fair value of the common stock warrants was determined using a Monte-Carlo simulation following a Geometric Brownian motion, using the following assumptions: annual volatility of 75%, risk-free rate of 0.9%, dividend yield of 0.0% and expected life of 5 years. Because the dilutive down-round financing was subject to stockholder approval, which had not happened at the time of the valuation, the model utilized the assumption that the down-round financing would not occur within the simulation.

The Company incurred legal, placement and other adviser fees of $1,894,000, including $754,000 in costs for warrants issued to placement agents. The total transaction costs were allocated among the instruments of the private placement investment based on their relative fair values as follows: $611,000 to subordinated convertible notes as deferred financing costs, $1,020,000 to Series A Preferred Stock as discount on Series A Preferred Stock and $263,000 to warrants as a charge to additional paid in capital.

Series A Convertible Preferred Stock

In connection with the private placement investment, the Company issued 2,416,785 shares of Series A Preferred Stock at $3.00 per share. Each share of the Series A Preferred Stock is convertible into one share of the Company's common stock. The price per share of Series A Preferred Stock and the conversion price for the common stock was less than the “market value” of the common stock of $3.82 (as defined in the rules of the Nasdaq Stock Market) on the date of execution of the definitive agreements. The Series A Preferred Stock does not pay a dividend, however, the holders are entitled to receive dividends on shares of Preferred Stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock. The Series A Preferred Stock has voting rights on a modified as-if-converted-to-common-stock-basis. The Series A Preferred Stock has a non-participating liquidation right equal to the original issue price plus accrued unpaid dividends, which are senior to the Company’s common stock. The Series A Preferred Stock can be converted to common shares at any time by the holders or, at the option of the Company, if the arithmetic average of the daily volume weighted average price of the common stock for the ten day period prior to the measurement date is greater than $8.00 per share and the average daily trading volume for the sixty day period immediately prior to the measurement date exceeds 100,000 shares. The conversion price is $3.00 per share, subject to certain adjustments.

The allocation of the proceeds and transaction costs based on relative fair values of the instruments resulted in recognition of a discount on the Series A Preferred Stock of $4,410,000, including a discount attributable to a beneficial conversion feature of $2,686,000, which was fully amortized from the date of issuance to the earliest redemption date in fiscal 2016. For the years ended January 31, 2018 and 2017, the Company recognized zero and $876,000, respectively, of amortization of the discount on Series A Preferred Stock as deemed dividends charged to additional paid in capital, computed under the effective interest rate method. The value of the beneficial conversion feature is calculated as the difference between the effective conversion price of the Series A Preferred Stock and the fair market value of the common stock into which the Series A Preferred Stock are convertible at the commitment date.

On November 1, 2012, upon shareholder approval, the convertible subordinated notes were converted into shares of Series A Convertible Preferred Stock. The convertible subordinated notes had an aggregate principal amount of $5,699,577 and converted into an aggregate of 1,583,210 shares of Preferred Stock. The Company recorded a loss upon conversion of $5,913,000, which represented the difference between the aggregate fair value of the Preferred Stock issued of $9,183,000, based on a $5.80 fair value per share, and the total of carrying value of the notes and unamortized deferred financing cost of $3,270,000. The shares of Series A Preferred Stock issued for the conversion of notes payable are recorded at their aggregate redemption value of $4,750,000 with the difference between the fair value and redemption value of $4,433,000 recorded as additional paid in capital. The fair value of the Preferred Stock was determined using a Monte-Carlo simulation based on the following assumptions: annual volatility of 75%, risk-free rate of 0.8% and dividend yield of 0.0%. The model also utilized the following assumptions to account for the conditions within the agreement: after four years, if the simulated common stock price fell below a price of $3.00 per share, the convertible preferred stock would automatically convert to common stock on a 1:1 basis moving forward at a price of $3.00 per share and a forced conversion if the simulated stock price exceeded $8.00 per share.

At any time following August 31, 2016, subject to the Subordination and Intercreditor Agreement among the preferred stockholders, the Company and Wells Fargo, each share of Series A Preferred Stock is redeemable at the option of the holder for an amount equal to the initial issuance price of $3.00 (adjusted to reflect stock splits, stock dividends or like events) plus any accrued and unpaid dividends thereon. The Series A Preferred Stock are classified as temporary equity as the securities are redeemable solely at the option of the holder.

In fiscal 2013, 1,050,000 shares of the Company's Series A Convertible Preferred Stock were converted into Common Stock. As a result, Series A Convertible Preferred Stock was reduced by $3,150,000, with the offsetting increase to Common Stock and Additional Paid-in Capital. As of January 31, 2018 and 2017, 2,949,995 shares of Series A Convertible Preferred Stock remained outstanding.

Common Stock Warrants

In conjunction with the private placement investment, the Company issued common stock warrants exercisable for up to 1,200,000 of the Company's common stock at an exercise price of $3.99 per share. The warrants expired on February 16, 2018.

On October 19, 2012, the Company also issued 200,000 warrants to its placement agents as a portion of the fees for services rendered in connection with the private placement investment. The warrants are exercisable through April 30, 2018 at a stated exercise price of $4.06 per share and can be exercised in whole or in part. The warrants also include a cashless exercise option that allows the holder to receive a number of shares of common stock based on an agreed upon formula in exchange for the warrants rather than paying cash to exercise. The warrants have no reset provisions. The warrants had a grant date fair value of $754,000, and are classified as equity on the consolidated balance sheet. The estimated fair value of the warrants was determined by using Monte-Carlo simulations based on the following assumptions: annual volatility of 75%, risk-free rate of 0.9%, dividend yield of 0.0% and expected life of five years.

The following table sets forth the warrants issued and outstanding as of January 31, 2018:



	Number of Shares Issuable	Weighted Average Exercise Price
Warrants - private placement	1,200,000	$	3.99
Warrants - placement agent	200,000	4.06
Total	1,400,000	$	4.00

The fair value of the private placement warrants was zero and $46,000 at January 31, 2018 and 2017, respectively. No warrants were exercised or canceled during fiscal 2017 and 2016.

Significant Accounting Policies (Policies)

12 Months Ended

Jan. 31, 2018

Accounting Policies [Abstract]

Basis of Presentation

Use of Estimates

Cash and Cash Equivalents

Receivables and Allowance for Doubtful Accounts

Receivables

Allowance for Doubtful Accounts

Concessions Accrual

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related assets. Estimated useful lives are as follows:



Computer equipment and software	3-4 years
Office equipment	5 years
Office furniture and fixtures	7 years
Leasehold improvements	Term of lease or estimated useful life, whichever is shorter

Depreciation expense for property and equipment in fiscal 2017 and 2016 was $774,000 and $1,100,000, respectively.

Leases

Debt Issuance Costs

Impairment of Long-Lived Assets

Capitalized Software Development Costs

Fair Value of Financial Instruments

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated by market data.

Revenue Recognition

We commence revenue recognition when all of the following criteria have been met:


•	Persuasive evidence of an arrangement exists,


•	Delivery has occurred or services have been rendered,


•	The arrangement fees are fixed or determinable, and


•	Collectibility is reasonably assured.

Multiple Element Arrangements

Terms used in evaluation are as follows:


•	VSOE (vendor-specific objective evidence) — the price at which an element is sold as a separate stand-alone transaction


•	TPE (third-party evidence) — the price of an element, charged by another company that is largely interchangeable in any particular transaction


•	ESP (estimated selling price) — our best estimate of the selling price of an element of the transaction

Software as a Service

Systems Sales

Maintenance and Support Services

Term Licenses

Software-Based Solution Professional Services

Audit Services

Concentrations

Business Combinations

Goodwill and Intangible Assets


•	significant underperformance relative to historical or projected future operating results;


•	significant changes in the manner of use of the acquired assets or the strategy for the overall business;


•	identification of other impaired assets within a reporting unit;


•	disposition of a significant portion of an operating segment;


•	significant negative industry or economic trends;


•	significant decline in the Company's stock price for a sustained period; and


•	a decline in the market capitalization relative to the net book value.

Determining whether a triggering event has occurred involves significant judgment by the Company.

The Company determined that it has one operating segment and one reporting unit.

Severances

Equity Awards

Common Stock Warrants

Income Taxes

Net Loss Per Common Share

In accordance with ASC 260, securities are deemed not to be participating in losses if there is no obligation to fund such losses.

Loss Contingencies

Recent Accounting Pronouncements

Significant Accounting Policies (Tables)

12 Months Ended

Jan. 31, 2018

Accounting Policies [Abstract]

Schedule of Bad Debt Expense

Bad debt expense for fiscal years 2017 and 2016 was as follows:



	2017		2016
Bad debt expense	$	234,000	$	121,000

Property and Equipment

Property and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related assets. Estimated useful lives are as follows:



Computer equipment and software	3-4 years
Office equipment	5 years
Office furniture and fixtures	7 years
Leasehold improvements	Term of lease or estimated useful life, whichever is shorter

Schedule of Capitalized Software Development Costs



	Fiscal Year
Amortization expense on internally-developed software included in:	2017		2016
Cost of systems sales	$	1,914,000	$	2,495,000
Cost of software as a service	186,000		271,000
Cost of audit services	13,000		5,000
Total amortization expense on internally-developed software	$	2,113,000	$	2,771,000

Fair Value of Liabilities on a Recurring Basis

The table below provides information on our liabilities that are measured at fair value on a recurring basis:



	Total Fair Value		Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
At January 31, 2018
Warrants liability (1)	$	—	$	—	$	—	$	—
Royalty liability (2)	2,469,000		—		—		2,469,000

At January 31, 2017
Warrants liability (1)	$	46,000	$	—	$	—	$	46,000
Royalty liability (2)	2,351,000		—		—		2,351,000

_______________

(1)

(2)

Schedule of Earnings Per Share, Basic and Diluted

The following is the calculation of the basic and diluted net loss per share of common stock:



	Fiscal Year
	2017			2016
Net loss	$	(3,099,214	)	$	(5,161,566	)
Less: deemed dividends on Series A Preferred Stock	—			(875,935		)
Net loss attributable to common shareholders	$	(3,099,214	)	$	(6,037,501	)
Weighted average shares outstanding - Basic	19,876,383			19,528,341
Stock options and restricted stock	—			—
Weighted average shares outstanding - Diluted	19,876,383			19,528,341
Basic net loss per share of common stock	$	(0.16	)	$	(0.31	)
Diluted net loss per share of common stock	$	(0.16	)	$	(0.31	)

Acquisitions and Divestitures (Tables)

12 Months Ended

Jan. 31, 2018

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The purchase price has been allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date as follows:



	Balance at September 8, 2016
Assets purchased:
Accounts and contracts receivable	$	792,000
Other assets	32,000
Internally-developed software	350,000
Intangible assets	650,000
Total assets purchased	1,824,000
Liabilities assumed:
Accounts payable and accrued liabilities	424,000
Net assets acquired	$	1,400,000
Cash paid	$	1,400,000

Debt (Tables)

12 Months Ended

Jan. 31, 2018

Debt Disclosure [Abstract]

Schedule of Minimum EBITDA Levels

The following table shows our minimum trailing four quarter period EBITDA covenant thresholds, as modified by the third amendment to the Credit Agreement:



For the four-quarter period ending	Minimum EBITDA
July 31, 2017	$	(1,250,000	)
October 31, 2017	(1,000,000		)
January 31, 2018	(700,000		)
April 30, 2018	(35,869		)
July 31, 2018	414,953
October 31, 2018	1,080,126
January 31, 2019	1,634,130
April 30, 2019	1,842,610
July 31, 2019	2,657,362
October 31, 2019 and each fiscal quarter thereafter	3,613,810

Summary of Term Loan and Line of Credit

Outstanding principal balances on debt consisted of the following at:



	January 31, 2018			January 31, 2017
Senior term loan	$	4,626,000		$	5,738,000
Capital lease	—			91,000
Total	4,626,000			5,829,000
Deferred financing cost	(128,000		)	(199,000		)
	4,498,000			5,630,000
Less: Current portion	(597,000		)	(747,000		)
Non-current portion of long-term debt	$	3,901,000		$	4,883,000

Schedule of Future Principal Repayments of Long-Term Debt

Future principal repayments of debt consisted of the following at January 31, 2018:



	Senior Term Loan (1)
2018	$	597,000
2019	4,029,000
Total repayments	$	4,626,000

_______________

(1) Term loan balance on the consolidated balance sheet is reported net of deferred financing costs of $128,000.

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

Goodwill and Intangible Assets (Tables)

12 Months Ended

Jan. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill Activity

The goodwill activity is summarized as follows:



	Goodwill
Balance at January 31, 2016	$	16,185,000
Adjustments to goodwill related to sale of business during fiscal 2016	(648,000		)
Balance at January 31, 2017 and January 31, 2018	$	15,537,000

Schedule of Intangible Asset Components

Intangible assets, net, consist of the following:



	January 31, 2018
	Estimated Useful Life	Gross Assets		Accumulated Amortization		Net Assets
Finite-lived assets:
Client relationships	5-15 years	$	5,805,000	$	3,308,000	$	2,497,000
Covenants not to compete	0.5-15 years	986,000		823,000		163,000
Supplier agreements	5 years	1,582,000		1,582,000		—
License agreement	15 years	4,431,000		1,256,000		3,175,000
Total		$	12,804,000	$	6,969,000	$	5,835,000



	January 31, 2017
	Estimated Useful Life	Gross Assets		Accumulated Amortization		Net Assets
Finite-lived assets:
Client relationships	5-15 years	5,805,000		2,692,000		3,113,000
Covenants not to compete	0.5-15 years	986,000		744,000		242,000
Supplier agreements	5 years	1,582,000		1,411,000		171,000
License agreement	15 years	4,431,000		960,000		3,471,000
Total		$	12,804,000	$	5,807,000	$	6,997,000

Amortization Schedule of Intangible Assets

Amortization over the next five fiscal years for intangible assets is estimated as follows:



	Annual Amortization Expense
2018	$	937,000
2019	885,000
2020	823,000
2021	786,000
2022	500,000
Thereafter	1,904,000
Total	$	5,835,000

Income Taxes (Tables)

12 Months Ended

Jan. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax (Expense) Benefit

Income taxes consist of the following:



	Fiscal Year
	2017			2016
Current tax (expense) benefit:
Federal	$	—		$	15,000
State	(11,573		)	(2,976		)
Total current provision	(11,573		)	12,024
Deferred tax benefit:
Federal	95,403			—
State	—			—
Total Deferred tax benefit	95,403			—
Current and deferred tax benefit	$	83,830		$	12,024

Schedule of Effective Income Tax Rate Reconciliation

The income tax benefit differs from the amount computed using the federal statutory income tax rate of 32.9 percent as follows:



	Fiscal Year
	2017			2016
Federal tax benefit at statutory rate of 32.9 percent	$	1,047,221		$	1,771,675
State and local taxes, net of federal benefit (expense)	195,117			84,402
Change in valuation allowance	4,504,875			(2,134,096		)
Permanent items:
Incentive stock options	(112,349		)	(361,245		)
Change in fair value of warrants liability	15,197			54,033
Goodwill basis difference recognized upon asset sale	—			(220,112		)
Section 162(m) disallowance	—			(22,647		)
Other	(24,673		)	(23,272		)
Reserve for uncertain tax position	(18,509		)	(262,525		)
R&D Credit (Federal)	219,305			1,045,453
R&D Credit (State)	(129,111		)	267,172
Tax Cuts and Jobs Act	(5,827,034		)	—
Other	213,791			(186,814		)
Income tax benefit	$	83,830		$	12,024

Schedule of Deferred Tax Assets and Liabilities

The income tax effects of these temporary differences and credits are as follows:



	January 31,
	2018			2017
Deferred tax assets:
Allowance for doubtful accounts	$	91,360		$	72,886
Deferred revenue	154,574			282,112
Accruals	71,286			120,165
Net operating loss carryforwards	10,617,120			15,141,861
Stock compensation expense	235,920			501,120
Property and equipment	108,537			132,934
AMT credit	—			102,144
R&D credit	1,144,058			1,050,100
Other	116,603			106,833
Total deferred tax assets	12,539,458			17,510,155
Valuation allowance	(11,812,860		)	(16,318,124		)
Net deferred tax assets	726,598			1,192,031
Deferred tax liabilities:
Definite-lived intangible assets	(726,598		)	(1,192,031		)
Total deferred tax liabilities	(726,598		)	(1,192,031		)
Net deferred tax liabilities	$	—		$	—

Summary of Income Tax Contingencies

A reconciliation of the beginning and ending amounts of gross unrecognized tax benefits (excluding interest and penalties) is as follows:



	2017			2016
Beginning of fiscal year	$	290,000		$	—
Additions for tax positions for the current year	62,000			59,000
Additions for tax positions of prior years	3,000			231,000
Subtractions for tax positions of prior years	(60,000		)	—
End of fiscal year	$	295,000		$	290,000

Stock-Based Compensation (Tables)

12 Months Ended

Jan. 31, 2018

Employee Stock Ownership Plan (ESOP), Shares in ESOP [Abstract]

Schedule of Stock Option Activity

A summary of stock option activity follows:



	Options		Weighted Average Exercise Price			Remaining Life in Years	Aggregate intrinsic value
Outstanding as of February 1, 2017	2,100,480		$	4.16
Granted	265,000		1.17
Exercised	—		—
Expired	(133,323	)	4.73
Forfeited	(59,001	)	2.24
Outstanding as of January 31, 2018	2,173,156		$	3.42	(1)	7.11	$	3,868,218
Exercisable as of January 31, 2018	1,626,404		$	3.98	(2)	6.67	$	2,894,999
Vested or expected to vest as of January 31, 2018	2,102,078		$	3.47		7.07	$	3,741,699

_______________


(1)	The exercise prices range from $1.06 to $8.10, of which 677,499 shares are between $1.06 and $2.00 per share, 525,240 shares are between $2.19 and $4.00 per share, and 970,417 shares are between $4.02 and $8.10 per share.


(2)	The exercise prices range from $1.18 to $8.10, of which 254,332 shares are between $1.18 and $2.00 per share, 442,155 shares are between $2.19 and $4.00 per share, and 929,917 shares are between $4.02 and $8.10 per share.

Schedule of Weighted-Average Assumptions

The fiscal 2017 and 2016 stock-based compensation was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions for each fiscal year:



	2017		2016
Expected life	6 years		6 years
Risk-free interest rate	2.65	%	2.10	%
Weighted average volatility factor	0.65		0.58
Dividend yield	—		—
Forfeiture rate	13	%	22	%

Schedule of Restricted Stock Award Activity

A summary of restricted stock award activity for fiscal 2017 and 2016 is presented below:



	Non-vested Number of Shares		Weighted Average Grant Date Fair Value
Non-vested balance at January 31, 2016	112,380		$	2.62
Granted	858,225		1.59
Vested	(112,380	)	2.56
Forfeited	—		—
Non-vested balance at January 31, 2017	858,225		$	1.59
Granted	295,337		1.17
Vested	(331,975	)	1.47
Forfeited	—		—
Non-vested balance at January 31, 2018	821,587		$	1.59

Private Placement Investment (Tables)

12 Months Ended

Jan. 31, 2018

Equity [Abstract]

Schedule of Investment Allocation

The proceeds were allocated among the instruments based on their relative fair values as follows:



	Fair Value at August 16, 2012		Proceeds Allocation at August 16, 2012
Instruments:
Series A Preferred Stock	$	9,907,820	$	6,546,146	(1)
Convertible subordinated notes payable	5,699,577		3,765,738		(2)
Warrants	2,856,000		1,688,116		(3)
Total investment	$	18,463,397	$	12,000,000

_______________

(1)

(2)

(3)

Schedule of Warrants Issued and Outstanding

The following table sets forth the warrants issued and outstanding as of January 31, 2018:



	Number of Shares Issuable	Weighted Average Exercise Price
Warrants - private placement	1,200,000	$	3.99
Warrants - placement agent	200,000	4.06
Total	1,400,000	$	4.00

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Significant Accounting Policies - Additional Information (Details)		12 Months Ended
	Dec. 13, 2013 ft²	Jan. 31, 2018 USD ($) segment shares	Jan. 31, 2017 USD ($) shares	Jan. 31, 2015 sqft	Feb. 01, 2018 USD ($)	Sep. 08, 2016 USD ($)
Allowance for Doubtful Accounts
Allowance for doubtful accounts		$ 349,058	$ 198,449
Bad debt expense		233,550	121,025
Concessions Accrual
Concessions Costs		48,000	52,000
Leases
Capital lease obligation		0	91,000
Capitalized Software Development Costs
Capitalized computer software, additions		1,836,000	1,979,000
Capitalized computer software, amortization		2,113,385	2,771,437
Research and development expense		5,352,189	7,453,638
Revenue Recognition
Deferred professional costs		471,000	500,000
Accumulated amortization of deferred costs		312,000	370,000
Amortization of professional expenses		$ 270,000	254,000
Goodwill and Intangible Assets
Number of operating segments \| segment		1
Number of reportable segments \| segment		1
Severances
Severance expenses		$ 58,000	360,000
Equity Awards
Share-based compensation expense		1,109,241	1,787,367
Income Taxes
Reserves for uncertain tax positions and corresponding interest and penalties		$ 286,000	$ 263,000
Net Earnings (Loss) Per Common Share
Preferred stock to common stock conversion ratio		1
Convertible Preferred Stock
Net Earnings (Loss) Per Common Share
Antidilutive securities (in shares) \| shares		2,949,995	2,949,995
Restricted Stock
Net Earnings (Loss) Per Common Share
Antidilutive securities (in shares) \| shares		293,568	377,135
Stock Options
Net Earnings (Loss) Per Common Share
Antidilutive securities (in shares) \| shares		2,173,156	2,100,480
Warrant
Net Earnings (Loss) Per Common Share
Antidilutive securities (in shares) \| shares		1,400,000	1,400,000
Employee Severance
Severances
Accrued severances		$ 0	$ 9,000
Minimum
Capitalized Software Development Costs
Useful life of capitalized computer software		3 years
Goodwill and Intangible Assets
Estimated useful life		1 year
Maximum
Capitalized Software Development Costs
Useful life of capitalized computer software		5 years
Goodwill and Intangible Assets
Estimated useful life		15 years
Interpoint Partners, LLC
Leases
Area under lease (sq. ft.) \| ft²	24,335
Duration of rent allowance	8 months
Meta
Leases
Area under lease (sq. ft.) \| sqft				10,350
Lease duration				2 months
Restricted Stock Award
Equity Awards
Required service period		1 year
Restricted Stock
Equity Awards
Shares surrendered for tax withholding (in shares) \| shares		32,033	8,241
Tax withholding obligations		$ 42,000	$ 12,000
Shares awarded (in shares) \| shares		220,337	828,225
Internally-developed software \| Opportune IT
Capitalized Software Development Costs
Intangible assets		$ 350,000				$ 350,000
Subsequent event \| Accumulated deficit \| ASU 2014-09
New Accounting Pronouncements and Changes in Accounting Principles
Cumulative impact of new accounting principle					$ 1,400,000

Significant Accounting Policies - Property, Plant, and Equipment (Details) - USD ($)	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Property, Plant and Equipment
Depreciation expense	$ 774,074	$ 1,099,957
Computer equipment and software \| Minimum
Property, Plant and Equipment
Property, plant and equipment, useful life	3 years
Computer equipment and software \| Maximum
Property, Plant and Equipment
Property, plant and equipment, useful life	4 years
Office equipment
Property, Plant and Equipment
Property, plant and equipment, useful life	5 years
Office furniture and fixtures
Property, Plant and Equipment
Property, plant and equipment, useful life	7 years

Significant Accounting Policies - Capitalized Software Development Costs (Details) - USD ($)	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Accounting Policies [Abstract]
Cost of systems sales	$ 1,914,000	$ 2,495,000
Cost of software as a service	186,000	271,000
Cost of audit services	13,000	5,000
Total amortization expense on internally-developed software	$ 2,113,385	$ 2,771,437

Significant Accounting Policies Significant Accounting Policies - Fair Value of Liabilities (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 31, 2018	Jan. 31, 2017	Aug. 16, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty liability	$ 2,469	$ 2,351
Warrants exercisable (in shares)			1,200,000
Exercise price (in USD per share)			$ 3.99
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty liability	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty liability	0	0
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty liability	2,469	2,351
Warrant
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liability	0	46
Warrant \| Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liability	0	0
Warrant \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liability	0	0
Warrant \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liability	$ 0	$ 46
Common Stock Warrant
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants exercisable (in shares)	1,400,000
Exercise price (in USD per share)	$ 4.00
Private Placement \| Common Stock Warrant
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants exercisable (in shares)			1,200,000
Exercise price (in USD per share)			$ 3.99

Significant Accounting Policies - Earnings Per Share (Details) - USD ($)	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Accounting Policies [Abstract]
Net loss	$ (3,099,214)	$ (5,161,566)
Less: deemed dividends on Series A Preferred Shares	0	(875,935)
Net loss attributable to common shareholders	$ (3,099,214)	$ (6,037,501)
Weighted average shares outstanding - Basic (in shares)	19,876,383	19,528,341
Stock options and restricted stock (in shares)	0	0
Weighted average shares outstanding - Diluted (in shares)	19,876,383	19,528,341
Basic net loss per common stock (in dollars per share)	$ (0.16)	$ (0.31)
Diluted net loss per common stock (in dollars per share)	$ (0.16)	$ (0.31)

Acquisitions and Divestitures - Narrative (Details) - USD ($)										1 Months Ended		3 Months Ended		12 Months Ended
	Dec. 01, 2016	Sep. 08, 2016	Nov. 21, 2014	Feb. 03, 2014	Oct. 25, 2013	Nov. 01, 2012	Aug. 16, 2012	Jun. 15, 2012	Dec. 07, 2011	Jun. 30, 2017	Dec. 31, 2016	Jul. 31, 2017	Jan. 31, 2017	Jan. 31, 2018	Jan. 31, 2017	Oct. 31, 2012
Business Acquisition [Line Items]
Cash paid														$ 0	$ 1,400,000
Common shares issued for convertible note and accrued interest (in shares)						1,583,210
Royalty liability													$ 2,350,754	2,469,193	2,350,754
Cash payment received from sale business														0	2,000,000
Interpoint
Business Acquisition [Line Items]
Total purchase price									$ 5,124,000
Cash paid									2,124,000
Common shares issued for convertible note and accrued interest (in shares)								1,529,729
Share price (in dollars per share)								$ 2.00
Meta
Business Acquisition [Line Items]
Total purchase price							$ 14,790,000
Cash paid							$ 13,288,000
Share price (in dollars per share)							$ 4.07
Issuance of common stock (in shares)							393,086
Percentage of outstanding shares acquired																100.00%
Montefiore Medical Center
Business Acquisition [Line Items]
Cash paid					$ 3,000,000
Periodic royalty payment term					6 years 6 months
Proprietary lease term					15 years
Ongoing royalty payments					$ 3,000,000
Royalty liability													2,351,000	$ 2,469,000	2,351,000
Unibased
Business Acquisition [Line Items]
Total purchase price				$ 6,500,000
Opportune IT
Business Acquisition [Line Items]
Total purchase price		$ 1,400,000
Cash paid		$ 1,400,000
Looking Glass Patient Engagement \| Disposal Group, Not Discontinued Operations
Business Acquisition [Line Items]
Cash payment received from sale business	$ 2,000,000
Pre-tax gain on sale of business															$ 238,000
Credit Agreement
Business Acquisition [Line Items]
Repayment of credit facility			$ 7,400,000
Convertible Subordinated Note \| Interpoint
Business Acquisition [Line Items]
Convertible subordinated note issuance									$ 3,000,000
Senior Notes \| Credit Agreement
Business Acquisition [Line Items]
Repayment of credit facility										$ 500,000	$ 500,000	$ 500,000	$ 500,000

Acquisitions and Divestitures - Assets Acquired and Liabilities Assumed (Details) - USD ($)		12 Months Ended
	Sep. 08, 2016	Jan. 31, 2018	Jan. 31, 2017
Liabilities assumed:
Cash paid		$ 0	$ 1,400,000
Opportune IT
Assets purchased:
Accounts receivable	$ 792,000
Other assets	32,000
Total assets purchased	1,824,000
Liabilities assumed:
Accounts payable and accrued liabilities	424,000
Net assets acquired	1,400,000
Cash paid	1,400,000
Internally-developed software \| Opportune IT
Assets purchased:
Intangible assets	350,000	$ 350,000
Intangible assets \| Opportune IT
Assets purchased:
Intangible assets	$ 650,000

Derivative Liabilities (Details) - USD ($)			12 Months Ended
Derivative Liabilities (Details) - USD ($)	Oct. 19, 2012	Aug. 16, 2012	Jan. 31, 2018	Jan. 31, 2017	Oct. 31, 2012
Derivative [Line Items]
Number of shares issuable (in shares)		1,200,000
Exercise price (in USD per share)		$ 3.99
Net of transaction costs, allocated to the warrants		$ 1,425,000
Fair value of warrants			$ 0	$ 46,191
Income recognized from changing in fair value of warrants			46,000	159,000
Estimate of Fair Value
Derivative [Line Items]
Fair value of warrants			$ 0	$ 46,000
Common Stock Warrant
Derivative [Line Items]
Number of shares issuable (in shares)			1,400,000
Exercise price (in USD per share)			$ 4.00
Placement Agent \| Common Stock Warrant
Derivative [Line Items]
Number of shares issuable (in shares)	200,000
Exercise price (in USD per share)	$ 4.06
Annual volatility	75.00%
Risk-free rate	0.90%
Dividend yield	0.00%
Expected life	5 years
Placement Agent \| Common Stock Warrant \| Estimate of Fair Value
Derivative [Line Items]
Fair value of warrants					$ 4,139,000
Derivative
Derivative [Line Items]
Annual volatility			57.40%	62.60%
Risk-free rate			0.00%	0.50%
Dividend yield			0.00%	0.00%
Expected life			0 years	1 year

Operating Leases (Details) - USD ($) $ in Thousands	12 Months Ended
Operating Leases (Details) - USD ($) $ in Thousands	Jan. 31, 2018	Jan. 31, 2017
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2018	$ 1,050
2019	978
2020	515
2021	521
2022	445
Total	3,509
Rent and leasing expense	1,234	$ 1,271
Facilities
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2018	1,039
2019	967
2020	504
2021	519
2022	445
Total	3,474
Equipment
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2018	11
2019	11
2020	11
2021	2
2022	0
Total	$ 35

Debt - Narrative (Details) - USD ($)			1 Months Ended			3 Months Ended		12 Months Ended
Debt - Narrative (Details) - USD ($)	Apr. 15, 2015	Nov. 21, 2014	Jun. 30, 2017	Dec. 31, 2016	May 31, 2016	Jul. 31, 2017	Jan. 31, 2017	Jan. 31, 2018	Jan. 31, 2017
Debt Instrument [Line Items]
Payment of principal								$ 1,111,689	$ 2,796,590
Deferred finance costs							$ 199,000	128,000	$ 199,000
Revolving Credit Facility
Debt Instrument [Line Items]
Commitment fee in connection with the term loan								18,000
Credit Agreement
Debt Instrument [Line Items]
Repayment of credit facility		$ 7,400,000
Amortization of financing costs		355,000
Credit Agreement \| Senior term loan
Debt Instrument [Line Items]
Revolving line of credit		10,000,000
Deferred finance costs								128,000
Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Revolving line of credit		$ 5,000,000						5,000,000
Borrowings outstanding								0
Credit Agreement \| Senior Notes
Debt Instrument [Line Items]
Repayment of credit facility			$ 500,000	$ 500,000		$ 500,000	$ 500,000
Payment of principal					$ 1,738,000
Minimum \| LIBOR \| Credit Agreement
Debt Instrument [Line Items]
Borrowing under the revolving loan bears interest at a rate equal to LIBOR plus	4.25%	4.25%
Minimum \| Base Rate \| Credit Agreement
Debt Instrument [Line Items]
Borrowing under the revolving loan bears interest at a rate equal to LIBOR plus	3.25%	3.25%
Maximum \| LIBOR \| Credit Agreement
Debt Instrument [Line Items]
Borrowing under the revolving loan bears interest at a rate equal to LIBOR plus	6.25%	5.25%
Maximum \| Base Rate \| Credit Agreement
Debt Instrument [Line Items]
Borrowing under the revolving loan bears interest at a rate equal to LIBOR plus	5.25%	4.25%
January 31, 2018 \| Credit Agreement
Debt Instrument [Line Items]
Minimum liquidity								5,000,000
February 1, 2018 through January 31, 2019 \| Credit Agreement
Debt Instrument [Line Items]
Minimum liquidity								4,000,000
February 1, 2019 \| Credit Agreement
Debt Instrument [Line Items]
Minimum liquidity								$ 3,000,000

Debt - Minimum EBITDA Levels (Details) - Credit Agreement	12 Months Ended
	Jan. 31, 2018 USD ($)
July 31, 2017
Debt Instrument [Line Items]
Minimum EBITDA level	$ (1,250,000)
October 31, 2017
Debt Instrument [Line Items]
Minimum EBITDA level	(1,000,000)
January 31, 2018
Debt Instrument [Line Items]
Minimum EBITDA level	(700,000)
April 30, 2018
Debt Instrument [Line Items]
Minimum EBITDA level	(35,869)
July 31, 2018
Debt Instrument [Line Items]
Minimum EBITDA level	414,953
October 31, 2018
Debt Instrument [Line Items]
Minimum EBITDA level	1,080,126
January 31, 2019
Debt Instrument [Line Items]
Minimum EBITDA level	1,634,130
April 30, 2019
Debt Instrument [Line Items]
Minimum EBITDA level	1,842,610
July 31, 2019
Debt Instrument [Line Items]
Minimum EBITDA level	2,657,362
October 31, 2019 and each fiscal quarter thereafter
Debt Instrument [Line Items]
Minimum EBITDA level	$ 3,613,810

Debt - Summary of Term Loan and Line of Credit (Details) - USD ($)	Jan. 31, 2018	Jan. 31, 2017
Debt Disclosure [Abstract]
Senior term loan	$ 4,626,000	$ 5,738,000
Capital lease	0	91,000
Total	4,626,000	5,829,000
Deferred financing cost	(128,000)	(199,000)
Long-term debt	4,498,000	5,630,000
Less: Current portion	(597,000)	(747,000)
Non-current portion of long-term debt	$ 3,901,000	$ 4,883,000

Debt - Schedule of Future Principal Repayments of Long-Term Debt (Details) - USD ($) $ in Thousands	Jan. 31, 2018	Jan. 31, 2017
Debt Instrument [Line Items]
Deferred finance costs	$ 128	$ 199
Senior Notes
Debt Instrument [Line Items]
Debt Payments Due by 2018	597
Debt Payments Due by 2019	4,029
Long-term Debt	$ 4,626

Goodwill and Intangible Assets - Schedule of Goodwill Activity (Details)	12 Months Ended
	Jan. 31, 2017 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning of period	$ 16,185,000
Adjustments to goodwill related to sale of business during fiscal 2016	(648,000)
Goodwill, end of period	$ 15,537,281

Goodwill and Intangible Assets - Schedule of Intangibles (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Intangible Assets, Net (Including Goodwill) [Abstract]
Gross Assets	$ 12,804	$ 12,804
Accumulated Amortization	6,969	5,807
Net Assets	$ 5,835	6,997
Minimum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	1 year
Maximum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	15 years
Client relationships
Intangible Assets, Net (Including Goodwill) [Abstract]
Gross Assets	$ 5,805	5,805
Accumulated Amortization	3,308	2,692
Net Assets	$ 2,497	$ 3,113
Client relationships \| Minimum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	5 years	5 years
Client relationships \| Maximum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	15 years	15 years
Covenants not to compete
Intangible Assets, Net (Including Goodwill) [Abstract]
Gross Assets	$ 986	$ 986
Accumulated Amortization	823	744
Net Assets	$ 163	$ 242
Covenants not to compete \| Minimum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	6 months	6 months
Covenants not to compete \| Maximum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	15 years	15 years
Supplier agreements
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	5 years	5 years
Gross Assets	$ 1,582	$ 1,582
Accumulated Amortization	1,582	1,411
Net Assets	$ 0	$ 171
License agreement
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	15 years	15 years
Gross Assets	$ 4,431	$ 4,431
Accumulated Amortization	1,256	960
Net Assets	$ 3,175	$ 3,471

Goodwill and Intangible Assets - Schedule of Future Amortization Expense (Details) - USD ($) $ in Thousands	Jan. 31, 2018	Jan. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
2018	$ 937
2019	885
2020	823
2021	786
2022	500
Thereafter	1,904
Net Assets	$ 5,835	$ 6,997

Income Taxes - Components of Income Tax Expense (Details) - USD ($)	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Current tax (expense) benefit:
Federal	$ 0	$ 15,000
State	(11,573)	(2,976)
Total current provision	(11,573)	12,024
Deferred tax benefit:
Federal	95,403	0
State	0	0
Total Deferred tax benefit	95,403	0
Income tax benefit	$ 83,830	$ 12,024

Income Taxes - Tax Provision at Statutory Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Income Tax Contingency [Line Items]
Statutory income tax rate	32.90%
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]
Federal tax benefit at statutory rate of 32.9 percent	$ 1,047,221	$ 1,771,675
State and local taxes, net of federal benefit (expense)	195,117	84,402
Change in valuation allowance	4,504,875	(2,134,096)
Incentive stock options	(112,349)	(361,245)
Change in fair value of warrants liability	15,197	54,033
Goodwill basis difference recognized upon asset sale	0	(220,112)
Section 162(m) disallowance	0	(22,647)
Other	(24,673)	(23,272)
Reserve for uncertain tax position	(18,509)	(262,525)
Tax Cuts and Jobs Act	(5,827,034)	0
Other	213,791	(186,814)
Income tax benefit	83,830	12,024
Federal
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]
R&D Credit	219,305	1,045,453
State
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]
R&D Credit	$ (129,111)	$ 267,172

Income Taxes - Schedule of Deferred Tax Assets and Tax Carryforwards (Details) - USD ($)	Jan. 31, 2018	Jan. 31, 2017
Deferred tax assets:
Allowance for doubtful accounts	$ 91,360	$ 72,886
Deferred revenue	154,574	282,112
Accruals	71,286	120,165
Net operating loss carryforwards	10,617,120	15,141,861
Stock compensation expense	235,920	501,120
Property and equipment	108,537	132,934
AMT credit	0	102,144
R&D credit	1,144,058	1,050,100
Other	116,603	106,833
Total deferred tax assets	12,539,458	17,510,155
Valuation allowance	(11,812,860)	(16,318,124)
Net deferred tax assets	726,598	1,192,031
Deferred tax liabilities:
Definite-lived intangible assets	(726,598)	(1,192,031)
Total deferred tax liabilities	(726,598)	(1,192,031)
Net deferred tax liabilities	$ 0	$ 0

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Income Tax Contingency [Line Items]
Valuation allowance	$ 11,812,860	$ 16,318,124
Change in valuation allowance	4,504,875	(2,134,096)
Reserves for uncertain tax positions and corresponding interest and penalties	286,000	263,000
Accrued interest and penalties	0	$ 0
Tax expense	5,800,000
Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Operating loss carryforwards	45,973,000
Change in valuation allowance	(4,505,000)
State
Income Tax Contingency [Line Items]
Operating loss carryforwards, subject to expire next twenty fiscal years	$ 18,230,000

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Beginning of fiscal year	$ 290	$ 0
Additions for tax positions for the current year	62	59
Additions for tax positions of prior years	3	231
Subtractions for tax positions of prior years	(60)	0
End of fiscal year	$ 295	$ 290

Major Clients - (Details) - Customer Concentration Risk - Accounts Receivable	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Customer One
Concentration Risk
Concentration risk, percentage	12.00%
Customer Two
Concentration Risk
Concentration risk, percentage	11.00%
Three Customers
Concentration Risk
Concentration risk, percentage		11.00%

Employee Retirement Plan (Details) - USD ($) $ in Thousands	12 Months Ended
Employee Retirement Plan (Details) - USD ($) $ in Thousands	Jan. 31, 2018	Jan. 31, 2017
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Matching contribution percent (up to)	100.00%
Maximum contribution as a percent of participant compensation	4.00%
Defined contribution plan, cost recognized	$ 524	$ 541

Employee Stock Purchase Plan (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Jun. 30, 2018	Jan. 02, 2018	Jan. 31, 2018	Jan. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award
Closing price		$ 1.68
$0.98 per share
Share-based Compensation Arrangement by Share-based Payment Award
Closing price			$ 1.06
$0.91 per share
Share-based Compensation Arrangement by Share-based Payment Award
Closing price			1.06
$1.02 per share
Share-based Compensation Arrangement by Share-based Payment Award
Closing price			$ 2.19
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares authorized to be purchased under Employee Stock Purchase Plan (in shares)			1,000,000
Employee Stock Purchase Plan, maximum annual contribution per employee, percent			10.00%
Employee Stock Purchase Plan, percent of fair market value, prior year			85.00%
Employee Stock Purchase Plan, percent of fair market value, current year			85.00%
Shares remaining available for grant (in shares)			455,265
Allocated share-based compensation expense			$ 19	$ 5
Cash received from purchase of shares under Employee Stock Purchase Plan			$ 45	$ 26
Employee Stock Purchase Plan \| $0.98 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan (in shares)			21,234
Stock purchased during period, price per share, Employee Stock Purchase Plan (in USD per share)			$ 0.98
Employee Stock Purchase Plan \| $0.91 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan (in shares)			26,048
Stock purchased during period, price per share, Employee Stock Purchase Plan (in USD per share)			$ 0.91
Employee Stock Purchase Plan \| $1.02 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan (in shares)				25,617
Stock purchased during period, price per share, Employee Stock Purchase Plan (in USD per share)				$ 1.02
Scenario, Forecast \| Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award
Purchase price discount	85.00%

Stock-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	Jan. 02, 2018 $ / shares	Jan. 31, 2018 USD ($) $ / shares shares	Jan. 31, 2017 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		2,173,156	2,100,480
Options issued (in shares)		265,000
Options expired (in shares)		133,323
Options forfeited (in shares)		59,001
Options exercised (in shares)		0
Exercise price range, lower range limit (in USD per share) \| $ / shares	$ 1.68
Options exercisable (in shares)		1,626,404
Weighted average grant date fair value (in USD per share) \| $ / shares		$ 0.65	$ 0.79
Total intrinsic value \| $		$ 0
Compensation cost not yet recognized \| $		$ 320
Weighted average period of recognition for compensation cost		1 year 2 months 9 days
Cash received from the exercise of options \| $		$ 0	$ 0
Cash received from purchases pursuant to the Employee Stock Purchase Plan \| $		$ 45	26
Change in control percentage		0.2
$1.06 to $8.10
Share-based Compensation Arrangement by Share-based Payment Award
Exercise price range, lower range limit (in USD per share) \| $ / shares		$ 1.06
Exercise price range, upper range limit (in USD per share) \| $ / shares		$ 8.1
$1.06 to $2.00
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		677,499
Exercise price range, lower range limit (in USD per share) \| $ / shares		$ 1.06
Exercise price range, upper range limit (in USD per share) \| $ / shares		$ 2.00
$2.19 to $4.00
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		525,240
Exercise price range, lower range limit (in USD per share) \| $ / shares		$ 2.19
Exercise price range, upper range limit (in USD per share) \| $ / shares		$ 4.00
Options exercisable (in shares)		442,155
$4.02 to $8.10
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		970,417
Exercise price range, lower range limit (in USD per share) \| $ / shares		$ 4.02
Exercise price range, upper range limit (in USD per share) \| $ / shares		$ 8.1
Options exercisable (in shares)		929,917
$1.18 to $8.10
Share-based Compensation Arrangement by Share-based Payment Award
Exercise price range, lower range limit (in USD per share) \| $ / shares		$ 1.18
Exercise price range, upper range limit (in USD per share) \| $ / shares		8.1
$1.18 to $2.00
Share-based Compensation Arrangement by Share-based Payment Award
Exercise price range, lower range limit (in USD per share) \| $ / shares		1.18
Exercise price range, upper range limit (in USD per share) \| $ / shares		$ 2
Options exercisable (in shares)		254,332
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Total intrinsic value \| $			0
Allocated share-based compensation expense \| $		$ 563	1,321
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average period of recognition for compensation cost		1 year 4 months 2 days
Allocated share-based compensation expense \| $		$ 546	$ 466
Compensation cost not yet recognized \| $		$ 741
2013 Incentive Compensation Plan \| Blended Equity Awards (Stock Options, Stock Appreciation Rights, Resticted Stock)
Share-based Compensation Arrangement by Share-based Payment Award
Shares authorized to issue		2,300,000
Term of options granted (or less)		10 years
Vesting period		3 years
Options outstanding		1,873,156	1,800,480
2013 Incentive Compensation Plan \| SAR's
Share-based Compensation Arrangement by Share-based Payment Award
SAR's outstanding (in shares)		0
Executive Inducement Grants
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		300,000
Options issued (in shares)		0	75,000
Options expired (in shares)		0	0
Options forfeited (in shares)		0	0
Options exercised (in shares)		0	0
Executive Inducement Grants \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding			300,000
Minimum \| 2013 Incentive Compensation Plan \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period		1 year
Maximum \| 2013 Incentive Compensation Plan \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period		4 years

Stock-Based Compensation - Summary of Stock Option Activity (Details)	12 Months Ended
	Jan. 31, 2018 USD ($) $ / shares shares
Options
Outstanding - beginning of year (in shares) \| shares	2,100,480
Granted (in shares) \| shares	265,000
Exercised (in shares) \| shares	0
Expired (in shares) \| shares	(133,323)
Forfeited (in shares) \| shares	(59,001)
Outstanding - end of year (in shares) \| shares	2,173,156
Options exercisable (in shares) \| shares	1,626,404
Vested or expected to vest - end of year (in shares) \| shares	2,102,078
Weighted Average Exercise Price
Outstanding - beginning of year (USD per share) \| $ / shares	$ 4.16
Granted (USD per share) \| $ / shares	1.17
Exercised (USD per share) \| $ / shares	0.00
Expired (USD per share) \| $ / shares	4.73
Forfeited (USD per share) \| $ / shares	2.24
Outstanding - end of year (USD per share) \| $ / shares	3.42
Weighted Average Exercise Price, Exercisable - end of year (USD per share) \| $ / shares	3.98
Weighted Average Exercise Price, Vested or expected to vest - end of year (USD per share) \| $ / shares	$ 3.47
Remaining Life in Years, Outstanding	7 years 1 month 10 days
Remaining Life in Years, Exercisable	6 years 8 months 1 day
Remaining Life in Years, Vested or expected to vest	7 years 26 days
Aggregate intrinsic value of outstanding options at year end \| $	$ 3,868,218
Aggregate intrinsic value of exercisable options at year end \| $	2,894,999
Aggregate intrinsic value of options vested or expected to vest at year end \| $	$ 3,741,699

Stock-Based Compensation - Weighted Average Assumptions (Details) - USD ($)	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Employee Stock Ownership Plan (ESOP), Shares in ESOP [Abstract]
Expected life	6 years	6 years
Risk-free interest rate	2.65%	2.10%
Weighted average volatility factor	65.00%	58.00%
Dividend yield	$ 0	$ 0
Forfeiture rate	13.00%	22.00%

Stock-Based Compensation - Schedule of Restricted Stock Award Activity (Details) - Restricted Stock - $ / shares	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Non-vested Number of Shares
Non-vested number of shares, beginning of period (in shares)	858,225	112,380
Granted (in shares)	295,337	858,225
Vested (in shares)	(331,975)	(112,380)
Forfeited (in shares)	0	0
Non-vested number of shares, end of period (in shares)	821,587	858,225
Weighted Average Grant Date Fair Value
Non-vested at beginning of period (USD per share)	$ 1.59	$ 2.62
Granted (USD per share)	1.17	1.59
Vested (USD per share)	1.47	2.56
Forfeited (USD per share)	0.00	0.00
Non-vested at end of period (USD per share)	$ 1.59	$ 1.59

Private Placement Investment - Additional Information (Details) - USD ($)			12 Months Ended
	Nov. 01, 2012	Aug. 16, 2012	Jan. 31, 2018	Jan. 31, 2017
Class of Stock [Line Items]
Warrants exercisable (in shares)		1,200,000
Exercise price (in USD per share)		$ 3.99
Common shares issued for convertible note and accrued interest (in shares)	1,583,210
Deferred finance costs			$ 128,000	$ 199,000
Warrants exercised (in shares)			0	0
Warrants canceled (in shares)			0	0
Common Stock Warrant
Class of Stock [Line Items]
Warrants exercisable (in shares)			1,400,000
Exercise price (in USD per share)			$ 4.00
Convertible Subordinated Notes Payable
Class of Stock [Line Items]
Convertible notes payable	$ 5,699,577
Private Placement
Class of Stock [Line Items]
Proceeds allocation		$ 12,000,000
Placement and other advisor fees		1,894,000
Cost of warrants issued		754,000
Deferred finance costs		611,000
Issuance of common stock warrants		263,000
Private Placement \| Series A Preferred Stock
Class of Stock [Line Items]
Proceeds allocation		$ 6,546,146
Issuance of common stock (in shares)		2,416,785
Preferred stock dividend rate (as a percent)		0.00%
Share price (in USD per share)		$ 3.00	$ 8.00
Common shares issued for convertible note and accrued interest (in shares)		1,583,210
Preferred stock, discount on shares		$ 1,020,000	$ 4,410,000
Private Placement \| Common Stock Warrant
Class of Stock [Line Items]
Proceeds allocation		$ 1,688,116
Warrants exercisable (in shares)		1,200,000
Exercise price (in USD per share)		$ 3.99
Private Placement \| Convertible Subordinated Notes Payable
Class of Stock [Line Items]
Proceeds allocation		$ 3,765,738
Convertible notes payable		$ 5,699,577

Private Placement Investment - Schedule of Investment Allocation (Details) - USD ($)			12 Months Ended
	Nov. 01, 2012	Aug. 16, 2012	Jan. 31, 2018
Series A Preferred Stock
Instruments:
Maximum conversion period	4 years
Private Placement
Instruments:
Total investment, Fair Value		$ 18,463,397
Proceeds allocation		12,000,000
Private Placement \| Common Stock Warrant
Instruments:
Warrants, Fair Value		2,856,000
Proceeds allocation		$ 1,688,116
Annual volatility		75.00%
Risk-free rate		0.90%
Dividend yield		0.00%
Expected life		5 years
Private Placement \| Convertible Subordinated Notes Payable
Instruments:
Convertible subordinated notes payable, Fair Value		$ 5,699,577
Proceeds allocation		3,765,738
Private Placement \| Series A Preferred Stock
Instruments:
Series A Preferred Stock, Fair Value		9,907,820
Proceeds allocation		$ 6,546,146
Conversion basis (in shares)		1
Maximum conversion period		4 years
Stock price at time of conversion (in USD per share)			$ 3.00
Annual volatility		75.00%
Risk-free rate		0.90%
Dividend yield		0.00%
Private Placement \| Minimum \| Series A Preferred Stock
Instruments:
Stock price at time of conversion (in USD per share)		$ 3.00
Private Placement \| Maximum \| Series A Preferred Stock
Instruments:
Stock price at time of conversion (in USD per share)		$ 8.00

Private Placement Investment - Series A Convertible Preferred Stock Narrative (Details) - USD ($)			12 Months Ended
	Nov. 01, 2012	Aug. 16, 2012	Jan. 31, 2018	Jan. 31, 2017	Jan. 31, 2014	Aug. 31, 2016
Class of Stock [Line Items]
Common shares issued for convertible note and accrued interest (in shares)	1,583,210
Redemption price per share (in USD per share)						$ 3.00
Series A Preferred Stock
Class of Stock [Line Items]
Accretion of Preferred Stock discount			$ 0	$ 876,000
Maximum conversion period	4 years
Shares converted (in shares)					1,050,000
Amount converted					$ 3,150,000
Convertible redeemable preferred stock, shares outstanding (in shares)				2,949,995
Convertible Subordinated Notes Payable
Class of Stock [Line Items]
Convertible notes payable	$ 5,699,577
Convertible Notes to Preferred Stock \| Series A Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in USD per share)	$ 5.80
Conversion basis (in shares)	1
Loss upon conversion	$ 5,913,000
Issuance of shares at redemption value for conversion of notes payable	9,183,000
Carrying value and unamortized deferred financing costs	3,270,000
Aggregate redemption value	4,750,000
Difference between fair value and redemption value recorded as additional paid in capital	$ 4,433,000
Annual volatility	75.00%
Risk-free rate	0.80%
Dividend yield	0.00%
Private Placement \| Series A Preferred Stock
Class of Stock [Line Items]
New issuance of series A convertible preferred stock (in shares)		2,416,785
Preferred stock, par value (in USD per share)		$ 3.00
Conversion basis (in shares)		1
Common stock, market value per share (in USD per share)		$ 3.82
Period over which share price is evaluated			10 days
Share price (in USD per share)		$ 3.00	$ 8.00
Period over which trade volume is evaluated			60 days
Average daily trading volume for period (in shares)			100,000
Stock price at time of conversion (in USD per share)			$ 3.00
Preferred stock, discount on shares		$ 1,020,000	$ 4,410,000
Beneficial conversion feature			$ 2,686,000
Common shares issued for convertible note and accrued interest (in shares)		1,583,210
Annual volatility		75.00%
Risk-free rate		0.90%
Dividend yield		0.00%
Maximum conversion period		4 years
Private Placement \| Convertible Subordinated Notes Payable
Class of Stock [Line Items]
Convertible notes payable		$ 5,699,577
Minimum \| Convertible Notes to Preferred Stock \| Series A Preferred Stock
Class of Stock [Line Items]
Stock price at time of conversion (in USD per share)	$ 3.00
Minimum \| Private Placement \| Series A Preferred Stock
Class of Stock [Line Items]
Stock price at time of conversion (in USD per share)		$ 3.00
Maximum \| Convertible Notes to Preferred Stock \| Series A Preferred Stock
Class of Stock [Line Items]
Stock price at time of conversion (in USD per share)	$ 8.00
Maximum \| Private Placement \| Series A Preferred Stock
Class of Stock [Line Items]
Stock price at time of conversion (in USD per share)		$ 8.00

Private Placement Investment - Common Stock Warrants Narrative (Details) - USD ($)	Oct. 19, 2012	Aug. 16, 2012	Jan. 31, 2018	Jan. 31, 2017	Oct. 31, 2012
Class of Stock [Line Items]
Warrants exercisable (in shares)		1,200,000
Weighted average exercise price (in USD per share)		$ 3.99
Net of transaction costs, allocated to the warrants		$ 1,425,000
Common Stock Warrant
Class of Stock [Line Items]
Warrants exercisable (in shares)			1,400,000
Weighted average exercise price (in USD per share)			$ 4.00
Private Placement \| Common Stock Warrant
Class of Stock [Line Items]
Warrants exercisable (in shares)		1,200,000
Weighted average exercise price (in USD per share)		$ 3.99
Fair value of warrants		$ 2,856,000
Annual volatility		75.00%
Risk-free rate		0.90%
Dividend yield		0.00%
Expected life		5 years
Placement Agent \| Common Stock Warrant
Class of Stock [Line Items]
Warrants exercisable (in shares)	200,000
Weighted average exercise price (in USD per share)	$ 4.06
Fair value of warrants	$ 754,000
Annual volatility	75.00%
Risk-free rate	0.90%
Dividend yield	0.00%
Expected life	5 years
Estimate of Fair Value \| Private Placement \| Common Stock Warrant
Class of Stock [Line Items]
Derivative liability			$ 0	$ 46,000
Estimate of Fair Value \| Placement Agent \| Common Stock Warrant
Class of Stock [Line Items]
Derivative liability					$ 4,139,000

Private Placement Investment - Schedule of Warrants Issued and Outstanding (Details) - $ / shares	Jan. 31, 2018	Aug. 16, 2012
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares issuable (in shares)		1,200,000
Weighted average exercise price (in USD per share)		$ 3.99
Common Stock Warrant
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares issuable (in shares)	1,400,000
Weighted average exercise price (in USD per share)	$ 4.00
Private Placement \| Common Stock Warrant
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares issuable (in shares)	1,200,000
Weighted average exercise price (in USD per share)	$ 3.99
Placement Agent \| Common Stock Warrant
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares issuable (in shares)	200,000
Weighted average exercise price (in USD per share)	$ 4.06

Schedule II - Valuation and Qualifying Accounts and Reserves (Details) - USD ($)	12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 198,449
Charged to Costs and Expenses	46,191	$ 158,922
Balance at End of Period	349,058	198,449
Allowance for doubtful accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	198,000	155,000
Charged to Costs and Expenses	234,000	121,000
Charged to Other Accounts	0	17,000
Deductions	(83,000)	(95,000)
Balance at End of Period	$ 349,000	$ 198,000

Major Clients	12 Months Ended
Major Clients	Jan. 31, 2018
Segment Reporting [Abstract]
MAJOR CLIENTS	MAJOR CLIENTS During fiscal year 2017, no individual client accounted for 10% or more of our total revenues. Two clients represented 12% and 11%, respectively, of total accounts receivable as of January 31, 2018. During fiscal year 2016, one individual client accounted for 10% or more of our total revenues. Three clients each represented 11% of total accounts receivable as of January 31, 2017.

Employee Retirement Plan	12 Months Ended
Employee Retirement Plan	Jan. 31, 2018
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
EMPLOYEE RETIREMENT PLAN	EMPLOYEE RETIREMENT PLAN The Company has established a 401(k) retirement plan that covers all associates. Company contributions to the plan may be made at the discretion of the board of directors. The Company matches 100% up to the first 4% of compensation deferred by each associate in the 401(k) plan. The total compensation expense for this matching contribution was $524,000 and $541,000 in fiscal 2017 and 2016, respectively.

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Jan. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation We are, from time to time, a party to various legal proceedings and claims, which arise in the ordinary course of business. We are not aware of any legal matters that could have a material adverse effect on the Company’s consolidated results of operations, financial position or cash flows.

Subsequent Events	12 Months Ended
Subsequent Events	Jan. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS We have evaluated subsequent events through April 25, 2018 and have determined that there are no subsequent events after January 31, 2018 for which disclosure is required.

Organization and Description of Business (Details)	12 Months Ended
Organization and Description of Business (Details)	Jan. 31, 2018 segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	1